To cite: Shah R, Raji MA,

Westra J. et al. Association of

co-prescribing of opioid and

benzodiazepine substitutes

fractures among older adults:

Prepublication history and

for this paper are available online. To view these files,

please visit the journal online

Accepted 13 December 2021

(http://dx.doi.org/10.1136/

bmjopen-2021-052057).

Received 06 April 2021

additional supplemental material

2021;11:e052057. doi:10.1136/

a cohort study. BMJ Open

bmjopen-2021-052057

with incident falls and

# **BMJ Open** Association of co-prescribing of opioid and benzodiazepine substitutes with incident falls and fractures among older adults: a cohort study

Rahul Shah <sup>(D)</sup>, <sup>1</sup> Mukaila A Raji <sup>(D)</sup>, <sup>2,3</sup> Jordan Westra, <sup>4</sup> Yong-Fang Kuo<sup>3,5</sup>

#### ABSTRACT

Objective Examine the association between the coprescribing of opioids, benzodiazepines, gabapentinoids (pregabalin and gabapentin) and selective serotonin reuptake inhibitors/serotonin and norepinephrine reuptake inhibitors (SSRI/SNRIs) in different combinations and the risk of falls and fractures.

Design Retrospective cohort study from 2015 to 2018. Setting Medicare enrolment and claims data. Participants Medicare beneficiaries with both chronic pain and anxiety disorders in 2016 with continuous enrolments in Parts A and B from 2015 to 2016 who were prescribed any combination of opioid, benzodiazepine. abapentinoid and SSRI/SNRI in 2017 for ≥7 days, as documented in their Medicare Part D coverage. Interventions Any combination of use of seven drug regimens (benzodiazepine +opioid; benzodiazepine +qabapentinoid; benzodiazepine +SSRI/ SNRI: opioid +gabapentinoid: opioid +SSRI/SNRI:

gabapentinoid +SSRI/SNRI; ≥3 drug classes). Main outcomes First event of fall and the first event of fracture after the index date, which was the first day of combination drug use that lasted  $\geq 7$  days in 2017. Results A total of 47 964 patients (mean [SD] age, 75.9 [7.1]; 78.0% woman) with diagnoses of both chronic pain and anxiety were studied. The median (Q1-Q3) duration of drug combination use was 26 (14-30) days. After adjusting for demographic characteristics, chronic conditions and history of hospitalisation and fall or fracture, the coprescribing of ≥3 drugs (adjusted HR [aHR], 1.38; 95% Cl 1.14 to 1.67) and opioid plus gabapentinoid (aHR, 1.18; 95% Cl 1.02 to 1.37) were associated with a high fall risk, compared with benzodiazepineplus opioid co-prescribing, findings consistent with the secondary analysis using inverse probability of treatment weighting with propensity scores. The co-prescribing of benzodiazepine plus gabapentinoid (aHR, 0.76; 95% Cl 0.59 to 0.98) was associated with lower fracture risk compared with the co-prescribing of benzodiazepine plus opioid, though this finding was not robust.

Conclusions Our findings add to comparative toxicity research on different combinations of gabapentinoids and serotonergic agents commonly prescribed with or as substitutes for opioids and benzodiazepines in patients with co-occurring chronic pain and anxiety.

## Strengths and limitations of this study

- This study is a retrospective cohort study with a large sample size of 47 964 Medicare beneficiaries.
- This study evaluates fall and fracture outcomes in patients with both chronic pain and anxiety disorders, two conditions that commonly co-exist in realworld clinical practice.
- Fall and fracture outcomes were compared across subsets of patients who were prescribed seven different drug combinations commonly used to treat chronic pain and anxiety, adding to the limited comparative toxicity research of combinations of opioids, benzodiazepines, gabapentinoids and selective serotonin reuptake inhibitors/serotonin norepinephrine reuptake inhibitors.
- Multivariable models accounting for demographic and clinical characteristics were used to evaluate outcomes, and inverse probability of treatment weighting with propensity score analyses was used to test for robustness of findings.
- One limitation is that the subsets of patients prescribed different drug combinations may differ in regards to their inherent fall risk, thus altering clinicians' decision to prescribe certain medications, that is, confounding by indication.

#### INTRODUCTION

Protected by copyright, including for uses related to text and data mining, AI training, and sim The rise in opioid prescribing in the USA over the last two decades has been associated with concomitant increases in the rates of opioid use disorder, overdose and mortality.1-3 Approximately one-third of opioid overdose deaths involve co-use of benzodiazepines (benzos),<sup>45</sup> a class of medication commonly prescribed for anxiety and sleep disorders.<sup>4-6</sup> The co-prescribing of opioids and benzos has steadily risen in recent years,<sup>57–9</sup> a reflection in part of the high rate of co-occurrence of pain and anxiety disorders.<sup>10</sup> In a retrospective analysis of claims data from 315428 commercially insured patients aged 18–64, Sun *et al*<sup>9</sup> reported that 9% used both an opioid and benzo in 2001, increasing to 17% in 2013.

1

C Author(s) (or their

employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BM.J.

Check for updates

For numbered affiliations see end of article.

**Correspondence to** Dr Rahul Shah: Rahul.shah@vumc.org Concurrent opioid and benzodiazepine use increases opioid overdose risk because of their synergistic depression of the central nervous system (CNS) and respiratory function.<sup>11 12</sup> Concurrent opioid and benzodiazepine use is also associated with increased risk of emergency room visit,<sup>9</sup> inpatient admission,<sup>9</sup> falls,<sup>13</sup> <sup>14</sup> fractures<sup>13</sup> <sup>14</sup> and death due to opioid overdose.<sup>5</sup>

In response, the 2016 Centers for Disease Control and Prevention (CDC) opioid prescribing guideline recommended that clinicians avoid co-prescribing opioids and benzodiazepines 'whenever possible'.<sup>15</sup> The Federal Drug Administration (FDA) has also strongly cautioned against their co-prescribing.<sup>16</sup> These strategies and other government, health system and payer policies have been associated with a decrease in the rate of opioid and benzodiazepine prescribing, separately and concurrently.<sup>17 18</sup> Restrictions on opioid prescribing have paralleled greater interest in the prescribing of the antiepileptic drugs gabapentinoids (GABA), ie, gabapentin and pregabalin as non-opioid analgesics.<sup>19–21</sup> Data from a nationally representative sample of 346177 Americans showed that GABA prescribing has increased from 1.2% in 2002 to 3.9% in 2015.<sup>21</sup> While FDA approved for a limited number of pain conditions, GABAs are widely used off-label to treat chronic pain despite limited evidence of efficacy and safety.<sup>19 21 22</sup> Other off-label use includes prescribing for anxiety disorders.<sup>23 24</sup> The premise for a shift to GABA as a safer alternative to opioids is not supported by evidence, as recent data showed associations of GABA use with dizziness, sedation, falls, fractures and overdose.<sup>19 20 22 25 26</sup>

While data have shown a shift towards GABA prescribing as a non-opioid analgesic after the 2016 CDC guideline, a similar change in the rate of non-benzodiazepine alternatives (selective serotonin reuptake inhibitors [SSRIs] and serotonin and norepinephrine reuptake inhibitors [SNRIs]) for treating comorbid anxiety in chronic pain patients is not clear. Modern evidence-informed prescribing guidelines strongly recommend SSRIs and SNRIs as first-line anxiolytic agents over benzodiazepines because of their better safety and efficacy profile than benzos.<sup>27-29</sup> SNRIs have an additional FDA indication for neuropathic pain and are commonly used for this purpose.<sup>30 31</sup> Unknown, however, are the differences in toxicity outcomes (eg, falls and fractures, overdose, hospitalisation, death) between opioid/benzo coprescribing and opioid-sparing or benzodiazepine-sparing combinations, such as those that use gabapentinoids or SSRI/ SNRIs.

Understanding these differences is especially important for older adults at higher risk of adverse events from the co-use of multiple psychoactive medications. Minimising falls and fractures is a key consideration when prescribing multiple medications for older adults. Comparative safety data can help clinicians choose combinations with the least toxicity to safely treat patients with chronic pain and anxiety disorders, two conditions that commonly co-occur in real-world clinical practice.<sup>10</sup> To address these knowledge gaps, this study aims to examine the association

between seven drug combinations commonly used to treat chronic pain and anxiety disorders and the risk of falls and fractures.

#### **METHODS**

#### **Data source**

This was a retrospective cohort study using enrolment and claims data from a 20% national sample of Medicare beneficiaries enrolled from 2015 to 2018. The data source included the Master Beneficiary Summary File (MBSF), Medicare Provider Analysis and Review (MEDPAR) file, Outpatient Standard Analytic File (OUTSAF), and by copyright, inc Carrier and Prescription Drug Event files. The institutional review board of the University of Texas Medical Branch approved this study.

#### **Study cohort**

The cohort selection flowchart is shown in online supplemental table 1. We selected Medicare beneficiaries aged 65 and older who were diagnosed with both chronic pain and anxiety in 2016; continuously enrolled in Parts A and B from 2015 to 2016; used some combination of opioid, benzo, SSRI/SNRI or GABA classes of medication in 2017 for at least 7 days; had 1 month Part D coverage prior to beginning the combination use; no prior combination use in the prior 30 days to initiation of a combination and had complete information in the data files. Chronic 5 pain and anxiety were ascertained using the Chronic **b** Conditions Data Warehouse (CCW) condition categories (online supplemental table 2). These categories are created by including beneficiaries with at least one inpadata mining, AI training, tient diagnosis or two non-drug claims of any type in the 2-year period.<sup>32</sup>

#### **Measurements**

#### Combination drug use

Combination of drug use was created by assessing which of the outpatient prescription drugs each beneficiary was using on each day of 2017. The first combination that was used 7 or more days in 2017 was used as the index combination; the first day of this combination use was the index date. If participants used a combination for  $\geq$ 7 days in 2017, they were followed into 2018 for complete prescription duration and outcome data. The index combination was categorised into seven groups: benzo plus opioid (benzo +opioid); benzo plus GABA (benzo +GABA); benzo plus SSRI or SNRI (benzo +SSRI/ SNRI); opioid plus GABA (opioid +GABA); opioid plus 8 SSRI or SNRI (opioid +SSRI/SNRI); GABA plus SSRI or SNRI (GABA +SSRI/SNRI) and  $\geq 3$  drugs from the four medication classes. We grouped SSRI/SNRI together as they share mechanisms of action. To ensure that the index combination was an initiation of combination, patients with any of the seven study combinations in the 30 days before the index date were excluded. The list of medications for each drug class is included in online supplemental table 3.

#### Fall and fracture

The study outcomes were (1) the first event of falls as any diagnosis and (2) the first event of fracture as a primary diagnosis after the index date. Falls and fractures were assessed using diagnosis codes from the Tenth Revision of the International Statistical Classification of Diseases and Related Health Problems (online supplemental table 4). Binary indicators were created for each of the outcomes and time to the first event was assessed from the index date. The median and interguartile duration of the initial drug combination was 26 (14-30) days (table 1). Therefore, patients were censored 30 days after the end of their initial drug combination, at loss of Medicare coverage, death or at the end of 6-month follow-up from the drug combination initiation.

#### **Covariates**

Sex, age category, race/ethnicity, Medicaid enrolment, US Census region, original reason for Medicare entitlement, history of fall or fracture, history of hospitalisation and chronic conditions were adjusted for in the analysis. Demographic variables were taken from the MBSF; history of fall, fracture or hospitalisation in the 12 months before the index date were created from MEDPAR, OUTSAF and Carrier files; and chronic conditions were taken from the CCW categories. We selected 19 chronic conditions related to the study outcomes: alcohol use disorders, Alzheimer's disease/dementia, arthritis, asthma, cancer (breast, colorectal, endometrial, lung, leukaemia, lymphoma), chronic kidney diseases (CKD), chronic obstructive pulmonary disease (COPD), depression, diabetes, drug use disorder, epilepsy, hearing impairment, liver disease, migraine/headache, mobility impairment, obesity, osteoporosis, spine injury and vision impairment.

#### Statistical analysis

Descriptive statistics were generated for each of the covariates with mean and SD for numeric variables and count and per cent for categorical variables across seven drug combination groups. The unadjusted fall or fracture rates for each group were estimated using the Kaplan-Meier method. Cox proportional hazard models were used to assess the effect of drug combination use on each of the outcomes separately adjusted for all variables. In addition, prespecified interactions were assessed in the model adjusted for all variables between drug combination and age, Alzheimer's/dementia status for both outcomes and history of fall/fracture for their correspondent outcome. Proportionality of hazards was tested by adding to the model the logarithm of the time to fall or fracture and assessing its significance. Furthermore, propensity score was generated with a multinomial logit model using average treatment effect estimation that considered all covariates listed in table 1. Backward elimination was used to select variables included in the propensity model, eventually eliminating the comorbidities of asthma and liver disease. Then we used inverse

probability of treatment weighting (IPTW) with propensity scores in Cox proportional hazard models to examine the effect of drug combination on outcomes and limit the effect of confounding by limitation across the study groups. Absolute standardised differences were used to assess balance across treatment groups. Because all variables were balanced following IPTW propensity score, no additional variables were included in the proportional hazards models. Finally, we conducted two sets of sensitivity analyses. First, we excluded patients with cancer diagnoses from our main analyses. Second, to better identify new initiation of drug combination, we repeated our main analyses with a 3-month lookback period, which included patients with part D coverage in the 3 months Š prior to beginning the combination use and did not have any studied combination in these 3 months. The sensi-tivity analyses were adjusted for all demographic and **g** clinical characteristics. All analyses were performed with including for uses rela SAS Enterprise V.7.12 at the Centers for Medicare and Medicaid Services Virtual Research Data Center (SAS Institute, Cary, North Carolina).

#### Patient and public involvement

Patients and the public were not involved in the design, conduct, reporting or dissemination plans of our research. The results of our study are not planned to be disseminated directly to study participants, as our data source is deidentified clinical data. However, this report will be available open access to all patient and clinician stakeholders.

## RESULTS

### **Baseline characteristics**

to text and data mining, A total of 47964 Medicare beneficiaries with diagnoses of both chronic pain and anxiety who used any of the ≥ seven study drug combinations were included in this study. Table 1 presents the baseline characteristics of uining, these individuals, stratified by the drug combinations. Of the full cohort, 10261 (21.4%) used the combination of benzo +opioid, 9541 (19.9%) used benzo +GABA, 4420 (9.2%) used benzo +SSRI/SNRI, 8625 (18.0%) S used opioid +GABA, 6843 (14.3%) used opioid +SSRI/ SNRI, 5499 (11.5%) used GABA +SSRI/SNRI and 2775 (5.8%) used any combination of  $\geq 3$  drugs from the four drug classes. Of those who used  $\geq 3$  drug classes, the most common combination was benzo +opioid+SSRI/SNRI (36%), followed by opioid +SSRI/SNRI+GABA (22%), benzo +opioid+GABA (19%), benzo +SSRI/SNRI+GABA (16%) and benzo +opioid+SSRI/SNRI+GABA (7%). The median (Q1-Q3) duration of drug combination use was 26 (14-30) days and mean (SD) was 32.0 (32.3) days. Overall, most individuals were women (78.0%) and white (87.6%), and the mean age was 75.9 (SD, 7.1) years. These characteristics were similar across the seven drug combination groups. A high proportion of the total study cohort had the comorbid chronic conditions of arthritis (78.2%), depression (62.3%), diabetes (37.4%), CKD

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.	Erasmushogeschool.	3MJ Open: first published as 10.1136/bmjopen-2021-052057 on 30 December 2021. Downloaded from http://bmjopen.bmj.com/ on May 24, 2025 at Department GEZ-LTA
--	--------------------	---

6

			aracteris	נוכא מווח כ		COLIMINO	is of stud	y particip	al ILS								
		AII		Benzo/o	pioid	GABA +{ SNRI	SSRI/	3+combc	~	Benzo+G	ABA	Benzo+S SNRI	SRI/	Opioid +(	GABA	Opioid +5 SNRI	SSRI/
	Total	47964	100%	10261	100%	5499	100%	2775	100%	9541	100%	4420	100%	8625	100%	6843	100%
Sex	Male	10570	22.0%	2510	24.5%	1181	21.5%	580	20.9%	1762	18.5%	957	21.7%	1818	21.1%	1762	25.7%
	Female	37394	78.0%	7751	75.5%	4318	78.5%	2195	79.1%	7779	81.5%	3463	78.3%	6807	78.9%	5081	74.3%
Age (mean, SD)		75.9	7.1	76.1	7.4	75.6	6.8	75.0	6.9	76.1	7.1	76.2	7.2	76.3	7.3	75.5	7.0
Age category	65–74	22662	47.2%	4784	46.6%	2652	48.2%	1443	52.0%	4440	46.5%	2000	45.2%	3958	45.9%	3385	49.5%
	75–84	17993	37.5%	3824	37.3%	2103	38.2%	998	36.0%	3607	37.8%	1726	39.0%	3203	37.1%	2532	37.0%
	85+	7309	15.2%	1653	16.1%	744	13.5%	334	12.0%	1494	15.7%	694	15.7%	1464	17.0%	926	13.5%
Race	White	42 008	87.6%	8876	86.5%	4834	87.9%	2420	87.2%	8668	90.9%	3869	87.5%	7682	89.1%	5659	82.7%
	Black	2579	5.4%	728	7.1%	251	4.6%	156	5.6%	211	2.2%	194	4.4%	414	4.8%	625	9.1%
	Hispanic	2168	4.5%	430	4.2%	260	4.7%	125	4.5%	414	4.3%	234	5.3%	328	3.8%	377	5.5%
	Other	1209	2.5%	227	2.2%	154	2.8%	74	2.7%	248	2.6%	123	2.8%	201	2.3%	182	2.7%
Region	MW	11107	23.2%	2294	22.4%	1310	23.8%	647	23.3%	2119	22.2%	977	22.1%	2191	25.4%	1569	22.9%
	NE	8204	17.1%	1506	14.7%	1037	18.9%	448	16.1%	2149	22.5%	915	20.7%	1222	14.2%	927	13.5%
	SO	20784	43.3%	4650	45.3%	2269	41.3%	1256	45.3%	3899	40.9%	1839	41.6%	3759	43.6%	3112	45.5%
	WE	7869	16.4%	1811	17.6%	883	16.1%	424	15.3%	1374	14.4%	689	15.6%	1453	16.8%	1235	18.0%
Original entitlement	Disabled/ ESRD	13297	27.7%	3213	31.3%	1409	25.6%	958	34.5%	1927	20.2%	1056	23.9%	2483	28.8%	2251	32.9%
	Old age	34667	72.3%	7048	68.7%	4090	74.4%	1817	65.5%	7614	79.8%	3364	76.1%	6142	71.2%	4592	67.1%
Medicaid dual	No	35329	73.7%	7435	72.5%	4013	73.0%	1911	68.9%	7683	80.5%	3419	77.4%	6194	71.8%	4674	68.3%
eligibility	Yes	12635	26.3%	2826	27.5%	1486	27.0%	864	31.1%	1858	19.5%	1001	22.6%	2431	28.2%	2169	31.7%
Number of	Mean, SD	32.0	32.3	25.7	25.5	46.4	44.6	36.8	40.3	36.9	34.5	32.1	28.8	27.7	27.9	26.7	24.0
days on drug combo	Median, Q1-Q3	26	14–30	20	12–30	30	20-59	30	15–30	30	17–39	28	15–30	21	44530	22	44 560
History of fall		8437	17.6%	1648	16.1%	1106	20.1%	604	21.8%	1414	14.8%	630	14.3%	1832	21.2%	1203	17.6%
History of fractu	Ire	3537	7.4%	710	6.9%	437	7.9%	270	9.7%	571	6.0%	242	5.5%	785	9.1%	522	7.6%
History of hospit	talisation	20997	43.8%	4400	42.9%	2529	46.0%	1435	51.7%	3404	35.7%	1669	37.8%	4116	47.7%	3444	50.3%
																	continued

2

1	1	ſ		
1		ŝ	l	
5	-	/	4	

		AII		Benzo/c	pioid	GABA + SNRI	SSRI/	3+comb	0	Benzo+	GABA	Benzo+9 SNRI	SSRI/	+ Dioid	+GABA	Opioid	SSRI/
Chronic conditions	Alcohol use disorders	2131	4.4%	417	4.1%	277	5.0%	131	4.7%	365	3.8%	181	4.1%	420	4.9%	340	5.0%
	Alzheimer/ dementia	10202	21.3%	1759	17.1%	1355	24.6%	665	24.0%	2008	21.0%	840	19.0%	2168	25.1%	1407	20.6%
	Arthritis	37490	78.2%	8073	78.7%	4314	78.5%	2205	79.5%	6636	69.6%	3323	75.2%	7147	82.9%	5792	84.6%
	Asthma	6543	13.6%	1409	13.7%	816	14.8%	408	14.7%	1168	12.2%	557	12.6%	1167	13.5%	1018	14.9%
	Cancer	6917	14.4%	1511	14.7%	781	14.2%	381	13.7%	1332	14.0%	700	15.8%	1230	14.3%	982	14.4%
	CKD	18364	38.3%	3753	36.6%	2373	43.2%	1150	41.4%	2924	30.6%	1535	34.7%	3521	40.8%	3108	45.4%
	COPD	14217	29.6%	3254	31.7%	1639	29.8%	930	33.5%	2274	23.8%	1110	25.1%	2697	31.3%	2313	33.8%
	Depression	29905	62.3%	4682	45.6%	4153	75.5%	2005	72.3%	6530	68.4%	2432	55.0%	6364	73.8%	3739	54.6%
	Diabetes	17962	37.4%	3460	33.7%	2537	46.1%	1088	39.2%	2949	30.9%	1601	36.2%	3293	38.2%	3034	44.3%
	Drug use disorder	5038	10.5%	1256	12.2%	478	8.7%	394	14.2%	553	5.8%	325	7.4%	1044	12.1%	988	14.4%
	Epilepsy	2075	4.3%	379	3.7%	281	5.1%	163	5.9%	360	3.8%	191	4.3%	397	4.6%	304	4.4%
	Hearing impairment	4553	9.5%	821	8.0%	592	10.8%	242	8.7%	968	10.1%	416	9.4%	861	10.0%	653	9.5%
	Hip/Pelvic fracture	1001	2.1%	196	1.9%	111	2.0%	79	2.8%	174	1.8%	55	1.2%	254	2.9%	132	1.9%
	Liver disease	3870	8.1%	814	7.9%	473	8.6%	250	9.0%	665	7.0%	344	7.8%	692	8.0%	632	9.2%
	Migraine/ headache	4362	9.1%	915	8.9%	532	9.7%	292	10.5%	852	8.9%	464	10.5%	734	8.5%	573	8.4%
	Mobility impairment	2744	5.7%	436	4.2%	453	8.2%	185	6.7%	425	4.5%	218	4.9%	528	6.1%	499	7.3%
	Obesity	13994	29.2%	2602	25.4%	1983	36.1%	903	32.5%	2262	23.7%	1185	26.8%	2717	31.5%	2342	34.2%
	Osteoporosis	\$ 7817	16.3%	1646	16.0%	868	15.8%	443	16.0%	1487	15.6%	701	15.9%	1552	18.0%	1120	16.4%
	Spine injury	1154	2.4%	247	2.4%	144	2.6%	89	3.2%	160	1.7%	82	1.9%	242	2.8%	190	2.8%
	Vision impairment	14508	30.2%	2929	28.5%	1772	32.2%	833	30.0%	3167	33.2%	1460	33.0%	2405	27.9%	1942	28.4%
CKD, chronic SSRI, selectiv	kidney disease; ( e serotonin reupt	SOPD, chro ake inhibito	onic obstru ors; WE, W	lctive pulm lest.	onary disea	ase; ESRD,	End-stage	renal dise	ase; GABA	, gabapen	tinoids; MW	V, Midwest	; NE, North	east; SD, s	standard d	eviation; S0	0, South;

Shah R, et al. BMJ Open 2021;11:e052057. doi:10.1136/bmjopen-2021-052057

Table 1 Continued

BMJ Open: first published as 10.1136/bmjopen-2021-052057 on 30 December 2021. Downloaded from http://bmjopen.bmj.com/ on May 24, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2021-052057 on 30 December 2021. Downloaded from http://bmjopen.bmj.com/ on May 24, 2025 at Department GEZ-LTA Erasmushogeschool Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

(38.3%), vision impairment (30.2%) and obesity (29.2%). Some groups that received different drug combinations differed in demographic characteristics and comorbid conditions. For example, some patient-level differences for those prescribed benzo +GABA versus opioid +SSRI/ SNRI were gender (81.5% vs 74.3% female, respectively), Medicaid dual eligibility (19.5% vs 31.7%) and comorbid arthritis (69.6% vs 84.6%).

#### Fall and fracture event analysis

The estimated cumulative risks for falls for the seven drug combinations over a 6-month period are presented as incidence curves in figure 1A (benzo +opioid: 10.1% at 6 months; benzo +GABA: 9.8%; benzo +SSRI/SNRI: 9.2%; opioid +GABA: 11.7%; opioid +SSRI/SNRI: 12.2%; GABA +SSRI/SNRI: 10.2%; ≥3 drugs: 13.7%). Figure 1B



Figure 1 Time to the incidence of (A) fall and (B) fracture after initiation of different drug combinations from Kaplan-Meier estimator. SSRI/SNRI, selective serotonin reuptake inhibitor/serotonin and norepinephrine reuptake inhibitor. GABA, gabapentinoid.

presents the curves for fracture (benzo +opioid: 3.9%) at 6months; benzo +GABA: 2.5%; benzo +SSRI/SNRI: 5.9%; opioid +GABA: 5.5%; opioid +SSRI/SNRI: 7.2%; GABA +SSRI/SNRI: 4.3%;  $\geq 3$  drugs: 4.5%).

## **Fall risk**

Table 2 presents the association between drug combination and fall risk as adjusted HRs from the multivariable model adjusted for demographic characteristics, chronic conditions and history of fall and hospitalisation in the prior year. Regimens with a combination of  $\geq 3$  drugs (aHR, 1.38; 95% CI 1.14 to 1.67) and opioid +GABA (aHR, 1.18; 95% CI 1.02 to 1.37) were associated with a higher risk of falls, compared with use of benzo +opioid. Characteristics that conferred an increased fall risk included older age (75–84: aHR, 1.36; 95% CI 1.22 to 1.52; ≥85: aHR, 1.74; 95% CI 1.51 to 2.00) and Medicare entitlement due to age (aHR, 1.14; 95% CI 1.02 to 1.27). History of fall (aHR, 2.48; 95% CI 2.25 to 2.75) and hospitalisation (aHR, 1.20; 95% CI 1.08 to 1.33) in the prior year were associated with a higher fall risk. Multiple comorbid conditions were also associated with increased fall risk: Alzheimer's/dementia (aHR, 1.37; 95% CI 1.24 to 1.52), cancer (aHR, 1.18; 95% CI 1.06 to 1.30), CKD (aHR, 1.20; 95% CI 1.09 to 1.33), COPD (aHR, 1.16; 95% CI 1.04 to 1.29), diabetes (aHR, 1.18; 95% CI 1.02 to 1.35) and history of drug use disorder (aHR, 1.24; 95% CI 1.03 to 1.49).

#### **Fracture risk**

Table 3 presents the association between drug combination and fracture risk from the multivariable model adjusted for demographic characteristics, chronic conditions and history of fracture and hospitalisation in the prior year. The use of benzo +GABA (aHR, 0.76; 95% CI 0.59 to 0.98) maintained a lower fracture risk compared with benzo +opioiduse. Older age (75-84: aHR, 1.23; 95% CI 1.02 to 1.46), history of fracture (aHR, 5.18; 95% CI 4.36 to 6.15) and hospitalisation (aHR, 1.40; 95% CI 1.18 to 1.66) in the prior year were associated with an increased risk of fracture. Comorbid conditions associated with an increased fracture risk were Alzheimer's/ dementia (aHR, 1.27; 95% CI 1.08 to 1.51), cancer (aHR, 1.27; 95% CI 1.08 to 1.49), CKD (aHR, 1.32; 95% CI 1.13 to 1.55) and history of drug use disorder (aHR, 1.35; 95% CI 1.03 to 1.77).

#### Interactions

Among the tested interactions, only the interaction of drug combination and Alzheimer's/dementia was statistically significant (p=0.0023) for the outcome of fall (online supplemental table 5). After stratifying by Alzheimer's/dementia status, ≥3 drugs (aHR, 1.71; 95% CI 1.22 to 2.39), benzo +GABA (aHR, 1.53; 95% CI 1.16 to 2.02) and opioid +GABA (aHR, 1.41; 95% CI 1.07 to 1.87) were associated with a higher risk of fall in patients with this comorbidity compared with the opioid +benzo combination; in individuals without Alzheimer's dementia,

no combinations were associated with a higher fall risk compared with the benzo +opioid combination.

#### **IPTW propensity score analysis**

IPTW with propensity score was used to limit the impact of confounding by indication across our study groups. Absolute standardised differences were used to assess balance across treatment groups after weighting and are presented in online supplemental table 6. The maximum absolute standardised differences across groups are displayed in figure 2, with all values estimated below 0.1. The results from the propensity score model for fall are presented in table 2, and the results for fracture are presented in table 3. The results from this model were  $\mathcal{P}$ consistent with the multivariable adjusted model for the 8 ğ combination use of ≥3 drug classes and opioid +GABA for the outcome of fall. Results of benzo +GABA were not significant for predicting a lower risk of fracture, as in the including multivariable model.

#### Sensitivity analyses

Two sets of sensitivity analyses were conducted to test the ğ robustness of findings from the multivariable model. First, uses rela excluding patients with cancer from the multivariable analysis showed the combination of  $\geq 3 \, drug$  classes predicting a higher risk of fall and fracture compared with the benzo +opioid combination (online supplemental table tec 7). Additionally, the combination of benzo +GABA was associated with a lower risk of fracture, consistent with the e Ä fully adjusted multivariable model in the main analyses. Second, excluding patients with any drug combination in the prior 3 months to the initiation of a new combination found that the combination of opioid +GABA was associated with a higher risk of fall and fracture compared З with the combination of benzo +opioid (online supplemental table 7). Online supplemental table 8 presents the 🧔 demographic and clinical characteristics of the full study  $\geq$ cohorts for our original analyses, of the model excluding training, and simi patients with cancer, and of the model with the 3-month lookback period.

#### DISCUSSION

We examined associations between different combinations of opioid, benzodiazepine, gabapentinoid and SSRI/SNRI classes of medications and the risk of falls lour and fractures among Medicare beneficiaries with co-existing chronic pain and anxiety disorders. We found  ${\ensuremath{\underline{\mathsf{G}}}}$ that—regardless of medication class—co-prescribing **g** three or more psychotropic medications was associated with increased risk of falls in this population of patients. This finding is consistent with prior research showing an association of psychotropic polypharmacy and greater morbidity in older adults.<sup>33 34</sup> The magnitude of the association between co-prescribing of  $\geq 3$  psychotropics and the risk of falls/fractures is significantly higher in those with Alzheimer's disease and other dementias compared with those without, a finding consistent with research

## Table 2 Association of drug combination with falls

		Model 1*: multivariable analysis	Model 21: IPTW propensity score analyis
		HR (95% CI)	HR (95% CI)
Drug combination‡	Benzo/opioid	REF	REF
	3+combo	1.38 (1.14 to 1.67)	1.28 (1.05 to 1.57)
	Benzo+GABA	1.05 (0.90 to 1.22)	1.09 (0.92 to 1.30)
	Benzo+SSRI or SNRI	0.85 (0.70 to 1.05)	0.90 (0.72 to 1.11)
	GABA +SSRI or SNRI	1.04 (0.88 to 1.23)	1.07 (0.89 to 1.27)
	Opioid +GABA	1.18 (1.02 to 1.37)	1.17 (1.00§ to 1.37)
	Opioid +SSRI or SNRI	1.09 (0.93 to 1.29)	1.08 (0.91 to 1.29)
Sex	Male	REF	
	Female	0.90 (0.80 to 1.01)	
Age	65–74	REF	
	75–84	1.36 (1.22 to 1.52)	
	85+	1.74 (1.51 to 2.00)	
Race	White	REF	
	Black	1.01 (0.82 to 1.25)	
	Hispanic	0.78 (0.61 to 1.00)	
	Other	1.11 (0.83 to 1.48)	
Region	WE	REF	
	MW	0.97 (0.84 to 1.12)	
	NE	0.85 (0.72 to 0.99)	
	SO	0.89 (0.78 to 1.02)	
Original entitlement	Disabled/ESRD	REF	
	Old age	1.14 (1.02 to 1.27)	
Medicaid dual eligibility	No	REF	
	Yes	1.01 (0.91 to 1.13)	
History of fall		2.48 (2.25 to 2.75)	
History of hospitalisation		1.20 (1.08 to 1.33)	
Chronic conditions (HR is for yes vs no)	Alcohol use disorders	1.20 (0.99 to 1.47)	
	Alzheimer/dementia	1.37 (1.24 to 1.52)	
	Arthritis	1.02 (0.89 to 1.16)	
	Asthma	1.13 (1.00 to 1.27)	
	Cancer	1.18 (1.06 to 1.30)	
	CKD	1.20 (1.09 to 1.33)	
	COPD	1.16 (1.04 to 1.29)	
	Depression	1.07 (0.97 to 1.19)	
	Diabetes	1.18 (1.02 to 1.35)	
	Drug use disorder	1.24 (1.03 to 1.49)	
	Epilepsy	0.93 (0.84 to 1.03)	
	Hearing impairment	1.07 (0.93 to 1.23)	
	Hip/pelvic fracture	0.72 (0.56 to 0.93)	
	Liver disease	1.12 (0.96 to 1.30)	
	Migraine/headache	1.12 (0.96 to 1.30)	
	Mobility impairment	0.87 (0.73 to 1.05)	
	Obesity	0.95 (0.86 to 1.06)	
	Osteoporosis	0.98 (0.87 to 1.11)	
	Spine injury	0.97 (0.87 to 1.10)	
	Vision impairment	1.20 (0.96 to 1.50)	

Continued

BMJ Open: first published as 10.1136/bmjopen-2021-052057 on 30 December 2021. Downloaded from http://bmjopen.bmj.com/ on May 24, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Table 2   Continued		
	Model 1*: multivariable analysis	Model 2†: IPTW propensity score analyis
	HR (95% CI)	HR (95% CI)

\*The multivariable analysis was adjusted for demographic variables, history of fall, history of hospitalisation and chronic conditions

†Inverse probability of treatment weighting with propensity score.
±The p value for the overall drug combination variable is 0.0011 for the fall models

\$The p value for the opioid +GABA combination in the propensity model is 0.0492 and the lower bound is 1.001.

CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ESRD, End-stage renal disease; GABA, gabapentinoid; IPTW, inverse probability of treatment weighting;

MW, Midwest; NE, Northeast; REF, reference group; SNRI, serotonin-norepinephrine reuptake inhibitor; SO, South; SSRI, selective serotonin reuptake inhibitor; WE, West.

showing amplified toxicity of couse of CNS-active medications in persons with dementia disorders.<sup>35</sup>

We also found opioid +GABA co-prescribing was independently associated with a greater risk of falls compared with opioid +benzo co-prescribing, a finding that persisted in the IPTW propensity score analysis. This finding is unexpected, as past research has shown associations of opioid +benzo co-prescribing with high rates of falls, fractures and deaths.<sup>459–1336</sup> It is unclear why opioid +GABA demonstrated higher fall risk than opioid +benzo, given that, alone or in combinations, all CNS-active agents (opioid, GABA and benzo) are associated with impaired alertness and motor response, which increase fall and fracture risk.<sup>87-40</sup> One possible explanation is that opioid +GABA users likely have more pain conditions (eg, knee, back or hip pain, peripheral neuropathy) that may affect mobility, balance and strength, thus further elevating the risk of falls, in addition to the fall risks from the CNS depressant effects of opioid +GABA. Yet, the higher fall risk remains significant in our analysis after adjusting for pain conditions, suggesting the possibility of other unmeasured fall-associated factors when opioids and GABA are used in combination. It is possible that the sedating effects of gabapentinoids, particularly in combination with opioids, are being underestimated by clinicians, and that this benzodiazepine-sparing combination is not inherently safer than the combination of opioids and benzodiazepines for the outcome of fall.

Our finding of decreased fracture risk with the benzo +GABA combination from the multivariable model was not robust and was inconsistent with the IPTW propensity score analysis, possibly a reflection of unmeasured variables that may influence likelihood of the complex outcome of fracture. Future research is needed to inform safe and effective combinations of medications in patients regarding fracture risk, possibily in more narrowly selected groups of patients.

For the sensitivity analysis that excludes patients with a combination in the prior 3 months, versus 1 month, as in the main analysis, the results are different compared with the fully adjusted multivariable model: the combination of opioid +GABA predicts a higher risk of both fall and fracture versus the combination of benzo +opioid. In addition to a halving of the sample size, it is possible that, compared with the main analysis' cohort, the demographic and clinical differences in this group of patients may be responsible for the differences in risk of fall and fracture. For example, patients in this group had older age distributions and lower rates of depression, drug disorder and obesity. The duration of their combination use was also shorter, and this cohort of patients had a lower proportion of the benzo +opioid and  $\geq 3$  drug combinations.

The absence of significant reduction in the risk of falls/ fractures between GABA+SSRI/SNRI and other opioidsparing or benzodiazepine-sparing combinations versus opioid +benzo co-prescribing was contrary to our expectations. Recent guidelines and federal and state policies urge against the combination of benzodiazepines and opioids. While this combination is now known to confer a high risk for morbidity and overdose mortality, there is not significant research that informs clinician prescribing of alternative combinations to treat comorbid chronic pain and anxiety. Despite the convention that opioidsparing and benzodiazepine-sparing drug combinations might be safer for patients, emerging research highlights ð the adverse effects of gabapentinoids, particularly in e combination with opioid analgesics. However, it is also important to recognise that both opioids and benzodiazepines, as well as gabapentinoids and SSRI/SNRIs, are important and effective medications in the right clinical contexts. Emerging comparative drug toxicity research should not be used to drive consequential prescribing decisions for patients without carefully weighing the benefits and harms within an individualised patient-centred ≥ framework, particularly in those with chronic pain and anxiety disorders. Often, the race to de-prescribe without a circumspect, cautious approach can lead to greater **g** harm for patients.<sup>41 42</sup>

There are several limitations to this study, including its retrospective design and the fact that drug prescriptions do not necessarily indicate their use. This study also did not analyse the association of dose within and across combination drug regimens, but only compared combinations by pharmacologic class. Additionally, confounding by indication is also a limitation of this study, common in observational research of drug effects. While this study seeks 8 to adjust for many clinical factors in the multivariable analysis, and test for robustness using IPTW propensity score analysis, it is possible that the indication for certain combinations was linked to fall or fracture outcomes, rather than outcomes being predicted solely by the combination. Indeed, that many of the statistically significant findings from the multivariable model were insignificant in the IPTW propensity score analysis highlight this point and the underlying challenges untangling adverse effects

#### Table 3 Association of

(		
_		

		Model 1*: multivariable analysis	Model 21: IPTW propensity score analysis
		HR (95% CI)	HR (95% CI)
Drug combination‡	Benzo/opioid	REF	REF
	3+combo	1.30 (0.97 to 1.74)	1.12 (0.82 to 1.53)
	Benzo+GABA	0.76 (0.59 to 0.98)	0.82 (0.62 to 1.09)
	Benzo+SSRI or SNRI	0.73 (0.52 to 1.02)	0.75 (0.53 to 1.06)
	GABA +SSRI or SNRI	1.05 (0.81 to 1.36)	1.09 (0.83 to 1.43)
	Opioid +GABA	1.19 (0.94 to 1.49)	1.15 (0.90 to 1.45)
	Opioid +SSRI or SNRI	1.12 (0.88 to 1.44)	1.17 (0.89 to 1.53)
Sex	Male	REF	
	Female	0.85 (0.70 to 1.02)	
Age	65–74	REF	
	75–84	1.23 (1.03 to 1.46)	
	85+	1.22 (0.98 to 1.53)	
Race	White	REF	
	Black	0.97 (0.67 to 1.40)	
	Hispanic	0.76 (0.50 to 1.15)	
	Other	1.29 (0.84 to 1.99)	
Region	WE	REF	
	MW	0.69 (0.54 to 0.87)	
	NE	0.99 (0.78 to 1.24)	
	SO	0.77 (0.63 to 0.94)	
Original entitlement	Disabled/ESRD	REF	
	Old age	1.06 (0.89 to 1.26)	
Medicaid dual eligibility	No	REF	
	Yes	0.85 (0.72 to 1.01)	
History of fracture		5.18 (4.36 to 6.15)	
History of hospitalisation		1.40 (1.18 to 1.66)	
Chronic conditions (HR is for yes	Alcohol use disorders	1.03 (0.76 to 1.41)	
vs no)	Alzheimer/dementia	1.27 (1.08 to 1.51)	
	Arthritis	0.83 (0.67 to 1.03)	
	Asthma	1.04 (0.86 to 1.26)	
	Cancer	1.27 (1.08 to 1.49)	
	CKD	1.32 (1.13 to 1.55)	
	COPD	1.15 (0.97 to 1.36)	
	Depression	0.90 (0.77 to 1.06)	
	Diabetes	1.01 (0.81 to 1.26)	
	Drug use disorder	1.35 (1.03 to 1.77)	
	Epilepsy	0.92 (0.79 to 1.08)	
	Hearing impairment	1.06 (0.85 to 1.32)	
	Hip/pelvic fracture	0.90 (0.66 to 1.21)	
	Liver disease	1.18 (0.93 to 1.49)	
	Migraine/headache	1.01 (0.79 to 1.30)	
	Mobility impairment	0.97 (0.74 to 1.27)	
	Obesity	0.91 (0.77 to 1.08)	
	Osteoporosis	1.18 (0.99 to 1.40)	
	Spine injury	0.95 (0.79 to 1.15)	
	Vision impairment	1.15 (0.87 to 1.53)	

\*The multivariable analysis was adjusted for demographic variables, history of fracture, history of hospitalisation and chronic conditions.

†Inverse probability of treatment weighting with propensity score.

‡The p value for the overall drug combination variable is 0.0008 for the fracture models.

CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; GABA, gabapentinoid; IPTW, inverse probability of treatment weighting; MW, Midwest; NE, Northeast; REF, reference group; SNRI, serotonin–norepinephrine reuptake inhibitor; SO, South; SSRI, selective serotonin reuptake inhibitor; WE, West.



**Figure 2** Maximum absolute standardised differences before and after inverse probability of treatment weighing with propensity score for the fall and fracture mode. CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease. CKD, chronic kidney disease. COPD, chronic obstructive pulmonary disease.

of drugs that may have different use cases, by approved indication or by real-life use pattern. Prescribers may be modifying their psychotropic prescribing practices to reflect their clinical perceptions of patients' risk of side effects such that high-fall risk patients may be given SSRI/SNRIs instead of benzodiazepines for anxiety, for example. In this vein, this study did not adjust severity in chronic pain or anxiety conditions, a factor that may influence clinician prescribing as well. Claims data may not capture such severity-based adjustment of choice and dosing of medications for pain and anxiety conditions, but this is an area for future quantitative and qualitative study. Finally, uncaptured and unmeasured differences in characteristics across patients being prescribed different drug regimens may explain predisposition to fall or fracture, beyond exposure to combination prescriptions.

In sum, this study found that the prescribing of  $\geq 3$  classes of medications and opioid +GABA co-prescribing were associated with a higher fall risk than opioid +benzo co-prescribing in patients with co-occurring chronic pain and anxiety. Our findings add to the body of research on the comparative toxicity profiles of different combinations of psychoactive medications (GABAs, SSRIs and

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

SNRIs) commonly used with or as substitutes for opioids or benzodiazepines in patients with chronic pain and anxiety disorders. Our findings may help clinicians weigh benefits and harms when prescribing drug combinations, especially in older patients with chronic pain and comorbid anxiety disorders, conditions that commonly co-occur in clinical practice. More research is required on the compound effects of multiple CNS-active agents on morbidity and mortality in older patients, particularly in the chronic use setting.

#### Author affiliations

<sup>1</sup>Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA

<sup>2</sup>Division of Geriatrics and Palliative Medicine, Department of Internal Medicine, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA <sup>3</sup>Sealy Center on Aging, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA

<sup>4</sup>Office of Biostatistics, Department of Preventive Medicine and Population Health, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA <sup>5</sup>Department of Preventive Medicine and Population Health, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA

#### Twitter Rahul Shah @RahulShahK

**Contributors** Y-FK and JW had full access to all of the data in this study and take full responsibility for the integrity of the data and accuracy of the data analysis. Concept and design: MAR, Y-FK. Acquisition, analysis or interpretation of the data: RS, MAR, JW, Y-FK. Drafting of the manuscript: RS, MAR, JW, Y-FK. Critical revision of the manuscript for important intellectual content: RS, MAR, JW, Y-FK. Statistical analysis: Y-FK, JW. Obtained funding: MAR, Y-AK. Administrative, technical or material support: Y-FK, JW. Supervision: Y-FK, MAR. Y-FK is responsible for the overall content of this study as the guarantor.

Funding This work was supported by grants R01DA039192 from the National Institute on Drug Abuse and P30AG024832 from the National Institute on Aging.

**Competing interests** All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi\_disclosure.pdf and declare: Raji and Kuo were recipients of the grant funding that supported this work from the US National Institute on Drug Abuse and National Institute on Aging; no financial relationships with any organisation that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

Patient consent for publication Not applicable.

Ethics approval The institutional review board of the University of Texas Medical Branch approved this study.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available. Data may be obtained from a third party and are not publicly available. The data used in this study are deidentified Medicare claims data, which may be provided to researchers upon request from the Centers for Medicare and Medicaid Services of the US.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

#### **ORCID** iDs

Rahul Shah http://orcid.org/0000-0001-6187-4690 Mukaila A Raji http://orcid.org/0000-0002-7460-7281

#### REFERENCES

- Wilson N. Drug and Opioid-Involved overdose deaths United States, 2017–2018. MMWR Morb Mortal Wkly Rep 2020;69.
- Understanding the Epidemic. Drug overdose | CDC injury center 2020.
- 3 CDC. Annual surveillance report of drug-related risks and outcomes, 2019.
- 4 Gladden RM. Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine — 25 states, July–December 2017 to January– June 2018. MMWR Morb Mortal Wkly Rep 2019:68.
- 5 Jones CM, McAninch JK. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. *Am J Prev Med* 2015;49:493–501.
- 6 Gomez AF, Barthel AL, Hofmann SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. *Expert Opin Pharmacother* 2018;19:883–94.
- 7 Hirschtritt ME, Delucchi KL, Olfson M. Outpatient, combined use of opioid and benzodiazepine medications in the United States, 1993-2014. *Prev Med Rep* 2018;9:49–54.
- 8 Rhee TG. Coprescribing of benzodiazepines and opioids in older adults: rates, correlates, and national trends. *J Gerontol A Biol Sci Med Sci* 2019;74:1910–5.
- 9 Sun EC, Dixit A, Humphreys K, et al. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ 2017;356:j760.
- 10 Asmundson GJG, Katz J. Understanding the co-occurrence of anxiety disorders and chronic pain: state-of-the-art. *Depress Anxiety* 2009;26:888–901.
- 11 Boon M, van Dorp E, Broens S, et al. Combining opioids and benzodiazepines: effects on mortality and severe adverse respiratory events. Ann Palliat Med 2020;9:542–57.
- 12 Jann M, Kennedy WK, Lopez G. Benzodiazepines: a major component in unintentional prescription drug overdoses with opioid analgesics. J Pharm Pract 2014;27:5–16.
- 13 Nurminen J, Puustinen J, Piirtola M, *et al.* Opioids, antiepileptic and anticholinergic drugs and the risk of fractures in patients 65 years of age and older: a prospective population-based study. *Age Ageing* 2013;42:318–24.
- 14 Musich S, Wang SS, Slindee LB, et al. Concurrent use of opioids with other central nervous System-Active medications among older adults. *Popul Health Manag* 2020;23:286–96.
- 15 CDC guideline for prescribing opioids for chronic pain United States, 2016. MMWR Recomm Rep 2016;65.
- 16 U.S. Food and Drug Administration. FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Drug safety communications, 2017. Available: https://www.fda.gov/drugs/drugsafety-and-availability/fda-drug-safety-communication-fda-warnsabout-serious-risks-and-death-when-combining-opioid-pain-or [Accessed 5 Oct 2020].
- 17 Jeffery MM, Hooten WM, Jena AB, et al. Rates of physician coprescribing of opioids and benzodiazepines after the release of the centers for disease control and prevention guidelines in 2016. JAMA Netw Open 2019;2:e198325.
- 18 Bohnert ASB, Guy GP, Losby JL. Opioid prescribing in the United States before and after the centers for disease control and prevention's 2016 opioid guideline. *Ann Intern Med* 2018;169:367–75.
- 19 Goodman CW, Brett AS. Gabapentin and pregabalin for pain is increased prescribing a cause for concern? N Engl J Med Overseas Ed 2017;377:411–4.

- 20 Goodman CW, Brett AS. Gabapentinoids for pain: potential unintended consequences. Am Fam Physician 2019;100:672–5.
- Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med 2018;178:292–4.
- Peckham AM, Evoy KE, Ochs L, et al. Gabapentin for offlabel use: evidence-based or cause for concern? Subst Abuse 2018;12:1178221818801311
   State D, Mittel H 1414
- 23 Feltner D, Wittchen H-U, Kavoussi R, et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008;23:18–28.
- 24 Lavigne JE, Heckler C, Mathews JL, et al. A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 Mg versus placebo for anxiety symptoms in breast cancer survivors. Breast Cancer Res Treat 2012;136:479–86.
- 25 Randolph AC, Lin Y-L, Volpi E, et al. Tricyclic antidepressant and/or γ-aminobutyric Acid-Analog use is associated with fall risk in diabetic peripheral neuropathy. J Am Geriatr Soc 2019;67:1174–81.
- 26 Gomes T, Greaves S, van den Brink W, et al. Pregabalin and the risk for opioid-related death: a nested case-control study. Ann Intern Med 2018;169:732–4.
- 27 Longo LP, Johnson B. Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives. *Am Fam Physician* 2000;61:2121
- 28 Gomez AF, Barthel AL, Hofmann SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. *Expert Opin Pharmacother* 2018;19:883–94.
- 29 Slee A, Nazareth I, Bondaronek P. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis [published correction appears in Lancet. 2019 Apr 27;393(10182):1698]. *Lancet* 2019;393:768–77.
- 30 Riediger C, Schuster T, Barlinn K, et al. Adverse effects of antidepressants for chronic pain: a systematic review and metaanalysis. Front Neurol 2017;8:307.
- 31 Kremer M, Salvat E, Muller A, et al. Antidepressants and gabapentinoids in neuropathic pain: mechanistic insights. *Neuroscience* 2016;338:183–206.
- 32 Centers for medicare & medicaid services chronic condition data warehouse: chronic condition categories. Available: https://www2. ccwdata.org/web/guest/condition-categories [Accessed 1 Mar 2020].
- 33 Maust DT, Gerlach LB, Gibson A, et al. Trends in central nervous system-active polypharmacy among older adults seen in outpatient care in the United States. JAMA Intern Med 2017;177:583–5.
- 34 Shmuel S, Lund JL, Alvarez C, et al. Polypharmacy and incident frailty in a longitudinal community-based cohort study. J Am Geriatr Soc 2019;67:2482–9.
- 35 Borda MG, Jaramillo-Jimenez A, Oesterhus R. Benzodiazepines and antidepressants: effects on cognitive and functional decline in Alzheimer's disease and Lewy body dementia [published online ahead of print, 2020 Dec 31]. *Int J Geriatr Psychiatry.* 2020.
- 36 Park TW, Saitz R, Ganoczy D, et al. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. *BMJ* 2015;350:h2698.
- 37 Saunders KW, Dunn KM, Merrill JO, *et al.* Relationship of opioid use and dosage levels to fractures in older chronic pain patients. *J Gen Intern Med* 2010;25:310–5.
- 38 Kinjo M, Setoguchi S, Schneeweiss S, et al. Bone mineral density in subjects using central nervous system-active medications. Am J Med 2005;118:1414.e7–e12.
- 39 Yue Q, Ma Y, Teng Y, et al. An updated analysis of opioids increasing the risk of fractures. PLoS One 2020;15:e0220216.
- 40 Takkouche B, Montes-Martínez A, Gill SS, et al. Psychotropic medications and the risk of fracture: a meta-analysis. *Drug Saf* 2007;30:171–84.
- 41 Dowell D, Haegerich T, Chou R. No shortcuts to safer opioid prescribing. *N Engl J Med* 2019;380:2285–7.
- 42 Hirschtritt ME, Olfson M, Kroenke K. Balancing the risks and benefits of benzodiazepines. *JAMA* 2021;325:347–8.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

## Supplementary Table 1. Study Cohort Selection

	Step	Ν
1	Medicare Enrollees in 2016	12,139,198
2	Had two years continuous enrollment (2015-2016)	5,906,400
3	Chronic pain and anxiety diagnoses, 2016	364,567
4	Any use of opioid, benzo, SSRI/SNRI, or GABA, 2017	254,658
5	Combination use of opioid, benzo, SSRI/SNRI, or GABA	199,949
6	Combination use for at least 7 days	155,552
7	Age 65 or older at combination use	85,586
8	Prior Part D enrollment	84,706
9	No Prior combination use of opioid, benzo, SSRI/SNRI, or GABA	47,997
10	Had complete information (birth date, region)	47,964

<sup>a</sup>55% of 2016 Medicare beneficiaries with chronic pain and anxiety disorders had a study combination prescription in 2017.

## Supplementary Table 2. ICD-10 Codes for (A) Chronic Pain and (B) Anxiety Disorders

Α				
Algorithms	Reference Period (# of Years) <sup>1</sup>	Valid ICD-9/MS DRG/HCPCS Codes	Valid ICD-10 Codes <sup>2</sup>	Number/Type of Claims to Qualify <sup>3</sup>
Fibromyalgia,	2 Years	DX 338.2, 338.21, 338.22, 338.23,	DX G89.21, G89.22, G89.28, G89.29, G89.3, G89.4,	At least one inpatient
Chronic Pain		338.29, 338.3, 338.4, 780.7, 780.71,	M54.10, M54.11, M54.12, M54.13, M54.14, M54.15,	claim OR two other
and Fatigue		729.1, 729.2 (any DX on the claim)	M54.16, M54.17, M54.18, M60.80, M60.811, M60.812,	non-drug claims of any
			M60.819, M60.821, M60.822, M60.829, M60.831,	service type during the
			M60.832, M60.839, M60.841, M60.842, M60.849,	two-year period
			M60.851, M60.852, M60.859, M60.861, M60.862,	
			M60.869, M60.871, M60.872, M60.879, M60.88,	
			M60.89, M60.9, M79.1, M79.10, M79.11, M79.12,	
			M79.18, M79.2, M79.7, R53.82 (any DX on the claim)	

<sup>1</sup>CCW data begins in 1999. When working with condition files prior to 2003, conditions with a reference period of 2–5 years will not have a sufficient length of data to fully meet the condition 2/CD-10 codes are effective 10/2015; effective dates for ICD-9 codes vary, but are valid through 09/2015. Researchers may be interested in confirming the code(s) of interest in the accompanying

claims data files.

<sup>3</sup>When two claims are required, they must occur at least one day apart. Note that the claims inclusion rules for these algorithms differ somewhat from the rules for the set of "CCW Chronic Condition Algorithms."

В

_					
	Algorithms	Reference Period (# of Years) <sup>1</sup>	Valid ICD-9/MS DRG/HCPCS Codes	Valid ICD-10 Codes <sup>2</sup>	Number/Type of Claims to Qualify <sup>3</sup>
	Anxiety	2 Years	DX 293.84, 300.00, 300.01, 300.02, 300.09,	DX F06.4, F40.00, F40.01, F40.02, F40.10, F40.11,	At least 1 inpatient OR
	Disorders		300.10, 300.20, 300.21, 300.22, 300.23,	F40.210, F40.218, F40.220, F40.228, F40.230, F40.231,	2 other non-drug
			300.29, 300.3, 300.5, 300.89, 300.9, 308.0,	F40.232, F40.233, F40.240, F40.241, F40.242, F40.243,	claims of any service
			308.1. 308.2. 308.3. 308.4. 308.9. 309.81.	F40.248, F40.290, F40.291, F40.298, F40.8, F40.9,	type with DX codes
			313 0 313 1 313 21 313 22 313 3 313 82	F41.0, F41.1, F41.3, F41.8, F41.9, F42, F42.2, F42.3,	
			515.0, 515.1, 515.21, 515.22, 515.5, 515.62,	F42.4, F42.8, F42.9, F43.0, F43.10, F43.11, F43.12,	
			313.83 (any DX on the claim)	F44.9, F45.8, F48.8, F48.9, F93.8, F99, R45.2, R45.5,	
				R45.6, R45.7 (any DX on the claim)	

<sup>1</sup>CCW data begins in 1999. When working with condition files prior to 2003, conditions with a reference period of 2–5 years will not have a sufficient length of data to fully meet the condition criteria in some years

<sup>2</sup>ICD-10 codes are effective 10/2015; effective dates for ICD-9 codes vary, but are valid through 09/2015. Researchers may be interested in confirming the code(s) of interest in the accompanying claims data files.

<sup>3</sup>When two claims are required, they must occur at least one day apart. Note that the claims inclusion rules for these algorithms differ somewhat from the rules for the set of "CCW Chronic Condition Algorithms.

## Supplementary Table 3. Medications Comprising Study Drug Classes

## **Benzodiazepines**

ALPRAZOLAM, ALPRAZOLAM INTENSOL, ALPRAZOLAM XR, AMBIEN, AMBIEN CR, AMBIENPAK, ATIVAN, CENTRAX, CHLORDIAZEPOXIDE, CHLORDIAZEPOXIDE & CLIDINIUM, CHLORDIAZEPOXIDE AND CLIDINIUM, CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HCL-CLIDINIUM BROM, CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE & CL, CHLORDIAZEPOXIDE HYDROCHLORIDE AND, CHLORDIAZEPOXIDE HYDROCHLORIDE-CLID, CHLORDIAZEPOXIDE HYDROCHLORIDE/CLID, CHLORDIAZEPOXIDE W/CLID BROM, CHLORDIAZEPOXIDE W/CLIDINIUM BROM, CHLORDIAZEPOXIDE-CLIDINIUM, CHLORDIAZEPOXIDE/CLIDINIUM, CHLORDIAZEPOXIDE/CLIDINIUM BROMIDE, CHLORDIAZEPOXIDEHYDROCHLORIDE AND C, CHLORDINIUM, CLINDEX, CLINOXIDE, CLOBAZAM, CLONAZEPAM, CLORAZEPATE, CLORAZEPATE DIPOTASSIUM, D-VAL, DALMANE, DIASTAT, DIASTAT ACUDIAL, DIASTAT PEDIATRIC, DIASTAT UNIVERSAL, DIAZEPAM, DIAZEPAM INTENSOL, DIAZEPAM NOVAPLUS, DIAZEPAM RECTAL DELIVERY SYSTEM, DIZAC, DORAL, DUO SPAZ, EDLUAR, ESTAZOLAM, ESZOPICLONE, FLURAZEPAM, FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE, FLURZEPAM, GABAVALE-5, GABAZOLAMINE, GABAZOLAMINE-0.5, GABAZOLPIDEM-5, GEN-XENE, HALCION, INTERMEZZO, KLONOPIN, KLONOPIN WAFERS, LI-GEN, LIBRAX, LIBRITABS, LIBRIUM, LORAZEPAM, LORAZEPAM AMERINET, LORAZEPAM INTENSOL, LORAZEPAM NOVAPLUS, LORAZEPAM-DEXTROSE, LORAZEPAM-SODIUM CHLORIDE, LUNESTA, MIDAZOLAM, MIDAZOLAM HCL, MIDAZOLAM HCL AMERINET CHOICE, MIDAZOLAM HCL NOVAPLUS, MIDAZOLAM HCL NOVATION, MIDAZOLAM HCL-DEXTROSE, MIDAZOLAM HCL-SODIUM CHLORIDE, MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE-SODIUM CHLO, MIDAZOLAM-DEXTROSE, MIDAZOLAM-SODIUM CHLORIDE, MITRAN, NIRAVAM, NOVAPLUS LORAZEPAM, NOVAPLUS MIDAZOLAM, NOVAPLUS MIDAZOLAM HCL, NOVAPLUS MIDAZOLAM HYDROCHLORIDE, ONFI, OXAZEPAM, PAXIPAM, POXI, PRAZEPAM, PREMIERPRO RX LORAZEPAM, PREMIERPRO RX MIDAZOLAM, PROBATE, PROSOM, QUARZAN, QUAZEPAM, RESTORIL, SENTRAZOLPIDEM PM-5, SERAX, SONATA, SYMPAZAN, TEMAZEPAM, TRANXENE, TRANXENE T-TAB, TRANXENE-SD, TRIAZOLAM, VALIUM, VALRELEASE, VERSED, XANAX, XANAX XR, ZALEPLON, ZEBRAX, ZETRAN, ZOLPIDEM, ZOLPIDEM TART, ZOLPIDEM TARTRATE, ZOLPIMIST

#### **Gabapentinoids**

ACTIVE-PAC WITH GABAPENTIN, CONVENIENCE PAK, CYCLO/GABA 10/300 PACK, FUSEPAQ FANATREX, GABA-V, GABAPENTIN, GABAPENTIN AVPAK, GABAPENTIN TAB 600MG, GABARONE, GRALISE, GRALISE STARTER PACK, HORIZANT, LYRICA, LYRICA CR, NEURAPTINE, NEURONTIN, PREGABALIN, SMART RX GABA-V, SMARTRX GABA KIT, THERAPENTIN-60

#### **Opioids**

ABSTRAL, ACET W/ HYDROCODONE, ACETAMIN W/ CODEINE, ACETAMIN W/CODEINE, ACETAMIN/BUTAL/CAFF/COD, ACETAMINOPHEN & HYDROCODONE, ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN AND TRAMADOL HYDROCHL, ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN W/CODEINE, ACETAMINOPHEN WITH CODEINE, ACETAMINOPHEN, CAFFEINE, AND DIHYDR, ACETAMINOPHEN-CAFFEINE-DIHYDROCODEI, ACETAMINOPHEN-CODEINE PHOSPHATE, ACETAMINOPHEN-HYDROCODONE BITARTRAT, ACETAMINOPHEN/BUTALBITAL/CAFFEINE/C, ACETAMINOPHEN/COD #4, ACETAMINOPHEN/CODEINE, ACETAMINOPHEN/CODEINE #2, ACETAMINOPHEN/CODEINE #3, ACETAMINOPHEN/CODEINE #4, ACETAMINOPHEN/CODEINE PHOSPHATE, ACETAMINOPHEN/HYDROCODONE BITARTRAT, ACETAMINOPHEN/OXYCODONE HYDROCHLORI, ACETAMINOPHEN/PENTAZOCINE HCL, ACETAMINOPHEN/TRAMADOL, ACETAMINOPHEN/TRAMADOL HYDROCHLORID, ACTIQ, ACTIVE-PREP KIT IV, ACTIVE-TRAMADOL KIT 8%, ALA-HIST AC, ALAHIST DHC, ALFENTA, ALFENTANIL, ALFENTANIL HCL, ALFENTANIL HCL NOVATION, ALFENTANIL NOVAPLUS, ALLAY, ALOR 5/500, ANEXSIA, ANODYNOS-DHC, ANOLOR DH 5, APAP AND CODEINE, APAP W/ CODEINE, APAP W/CODEINE, APAP W/HYDROCODONE, APAP W/OXYCODONE, APAP/CODEINE, APAP/HYDROCODONE, APAP/HYDROCODONE BITARTRATE, APAP/HYDROCODONE BITARTRATE HS, APAP/HYDROCODONE ES, APAP/OXYCODONE, APAP/PENTAZOCINE HCL, APAP/TRAMADOL, APAP/TRAMADOL HCL, APAP/TRAMADOL HYDROCHLORIDE, ARYMO ER, ASCOMP W/CODEINE, ASPIRIN W/CODEINE, ASPIRIN W/OXYCODONE, ASPIRIN, CAFFEINE, AND DIHYDROCODEI, ASPIRIN/BUTALBITAL/CAFFEINE/CODEINE, ASPIRIN/CARISOPRODOL/CODEINE, ASPIRIN/CODEINE, ASPIRIN/OXYCODONE, ASTRAMORPH, ASTRAMORPH PF, ASTRAMORPH/PF, ATROPINE AND DEMEROL, ATUSS HS, AVINZA, AZDONE, B & O SUPPRETTES 15A, B & O SUPPRETTES 16A, BANCAP H.C., BANCAP HC, BELLADONNA/OPIUM, BROVEX CB, BROVEX CBX, BROVEX PB C, BROVEX PB CX, BUPIV/FENTANYL CITR/SOD CL, BUPIV/HYDROMORPH/SOD CL, BUPIVACAINE HCL-FENTANYL CITRATE-SO, BUT/APAP/CAFF/COD, BUT/ASP/CAFF W/CODEINE, BUTAL/APAP/CAFF/COD, BUTALBITAL COMPOUND W/CODEINE, BUTALBITAL COMPOUND/CODEINE, BUTALBITAL, ACETAMINOPHEN AND CAFFE, BUTALBITAL, ASPIRIN, CAFFEINE & COD,

BUTALBITAL, ASPIRIN, CAFFEINE, AND CO, BUTALBITAL-ACETAMINOPHEN-CAFFEINE-C, BUTALBITAL-APAP-CAFFEINE-CODEINE, BUTALBITAL-ASPIRIN-CAFFEINE-CODEINE, BUTALBITAL/APAP/CAFF/COD, BUTALBITAL/APAP/CAFFEINE/CODEINE, BUTALBITAL/ASA/CAFF/COD, BUTALBITAL/ASPIRIN/CAFFEINE W/CODEI, BUTALBITAL/ASPIRIN/CAFFEINE/CODEINE, BUTINAL W/CODEINE, CAPITAL W/CODEINE, CARBINOXAMINE-HYDROCODONE-PSEUDOEPH, CARBINOXAMINE/HYDROCODONE/PSE, CARISOPRODOL/ASPIRIN/CODEINE, CETA PLUS, CHLORPHENIRAMINE AND CODEINE, CO-GESIC, COCET, COCET PLUS, CODAR AR, CODAR D, CODAR GF, CODEGESIC, CODEINE, CODEINE PHOSPHATE, CODEINE PHOSPHATE & ACETAMINOPHEN, CODEINE SULFATE, CODITUSSIN DAC, COMBUNOX, CONZIP, COTAB A, COTAB AX, CYTUSS-HC NR, D-TANN HC, DAMASON-P, DAZIDOX, DEMEROL, DEMEROL APAP, DEMEROL HYDROCHLORIDE, DEPODUR, DEXTROSE/MORPHINE SULFATE, DHC PLUS, DILAUDID, DILAUDID-5, DILAUDID-HP, DISKETS DISPERSIBLE, DOLACET, DOLAGESIC, DOLFEN, DOLOPHINE HCL, DOLOREX FORTE, DONATUSS DC, DROPERIDOL/FENTANYL CITRATE, DSUVIA, DUOCET, DURADYNE DHC, DURAGESIC, DURAMORPH, DVORAH, DYTAN-HC, EMBEDA, EMPIRIN W/CODEINE, EN-PAIN, ENDACOF-C, ENDOCET, ENDOCODONE, ENDODAN, ENOVARX-TRAMADOL, ETH-OXYDOSE, EXALGO, EZ III, FEBRIDYNE, FENTANYL, FENTANYL CITRATE, FENTANYL CITRATE NOVAPLUS, FENTANYL CITRATE-DEXTROSE, FENTANYL CITRATE-ROPIVACAINE HCL-SO, FENTANYL CITRATE-SODIUM CHLORIDE, FENTANYL CITRATE/ROPIVACAINE HCL/SO, FENTANYL CITRATE/SODIUM CHLORIDE, FENTANYL NOVAPLUS, FENTANYL ORALET, FENTANYL TRANSDERMAL SYSTEM, FENTANYL TRANSDERMAL SYSTEM NOVAPLU, FENTANYL TROCHE, FENTANYL/BUPIVACAINE/EPINEPHRINE/SO, FENTANYL/BUPIVACAINE/SODIUM CHLORID, FENTANYL/ROPIVACAINE/SODIUM CHLORID, FENTORA, FIORICET W/CODEINE, FIORICET WITH CODEINE, FIORINAL W/CODEINE, FIORTAL W/CODEINE, FUSEPAQ SYNAPRYN, G-2, G-3, GESIC 5, H-C TUSSIVE-NR, HC/PE/DBROM, HISTEX HC, HISTUSS HC, HISTUSSIN HC, HY-PHEN, HYCET, HYCO-PAP, HYCOMED, HYCOTAB, HYDROCET, HYDROCOD BIT & ACET, HYDROCODONE BIT & ACET, HYDROCODONE BIT AND ACET. HYDROCODONE BITART/ACET, HYDROCODONE BITART/IBU, HYDROCODONE BITARTRATE & ACET, HYDROCODONE BITARTRATE & ACETAMINOP, HYDROCODONE BITARTRATE & IBUPROFEN, HYDROCODONE BITARTRATE AND ACETAMIN, HYDROCODONE BITARTRATE AND IBUPROFE, HYDROCODONE BITARTRATE-ACETAMINOPHE, HYDROCODONE BITARTRATE-IBUPROFEN, HYDROCODONE BITARTRATE/ACETAMINOPHE, HYDROCODONE BITARTRATE/APAP, HYDROCODONE BITARTRATE/IBUPROFEN, HYDROCODONE W/ APAP, HYDROCODONE W/APAP, HYDROCODONE-APAP, HYDROCODONE-CHLORPHENIRAMINE MALEAT, HYDROCODONE/ACET, HYDROCODONE/ACETAMINOPHEN, HYDROCODONE/APAP, HYDROCODONE/IBU, HYDROCODONE/IBUPROFEN, HYDROGESIC, HYDROMORPHONE, HYDROMORPHONE HCL, HYDROMORPHONE HCL-BUPIVACAINE HCL-S, HYDROMORPHONE HCL-DEXTROSE, HYDROMORPHONE HCL-ROPIVACAINE HCL-S, HYDROMORPHONE HCL-SODIUM CHLORIDE, HYDROMORPHONE HCL/SODIUM CHLORIDE, HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE-SODIUM, HYDROSTAT IR, HYSINGLA ER, IBUDONE, IBUPROFEN W/ HYDROCODONE, INFUMORPH, INFUMORPH 200, INFUMORPH 500, INNOVAR, IONSYS, ISOLLYL W/CODEINE, J-COF DHC, KADIAN, LAZANDA, LEVO-DROMORAN, LEVORPHANOL TARTRATE, LIQUICET, LORCET, LORCET 10/650, LORCET HD, LORCET PLUS, LORCET-HD, LORTAB, LORTAB 10/325, LORTAB 10/500, LORTAB 2.5/500, LORTAB 5/325, LORTAB 5/500, LORTAB 7.5/325, LORTAB 7.5/500, LORTAB ASA, LORTAB ELIXIR, LORTAB LIQUID, M-CLEAR, M-END MAX D, M-END PE, M-END WC, MAGNACET, MAR-COF BP, MARGESIC #3, MARGESIC-H, MAXIDONE, MEDIPAIN 5, MEGAGESIC, MEGAMOR, MEPEREDINE, MEPERGAN, MEPERGAN FORTIS, MEPERIDINE, MEPERIDINE HCL, MEPERIDINE HCL-PROMETHAZINE HCL, MEPERIDINE HCL-SODIUM CHLORIDE, MEPERIDINE HCL/PROMETHAZINE HCL, MEPERIDINE HCL/SODIUM CHLORIDE, MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE-SODIUM CHL, MEPERIDINE HYDROCHLORIDE/PROMETHAZI, MEPERIDINE-PROMETHAZINE, MEPERIDINE/PROMETHAZINE, MEPERITAB, MEPROZINE, METHADONE, METHADONE DISP, METHADONE HCL, METHADONE HCL CONCENTRATE, METHADONE HCL INTENSOL, METHADONE HCL-SODIUM CHLORIDE, METHADONE HYDROCHLORIDE, METHADOSE, METHADOSE DISP, MITIGO, MORPHABOND ER, MORPHINE, MORPHINE SULF, MORPHINE SULFATE, MORPHINE SULFATE CONTROLLED RELEASE, MORPHINE SULFATE CR, MORPHINE SULFATE ER, MORPHINE SULFATE IMMEDIATE RELEASE, MORPHINE SULFATE IN 5% DEXTROSE, MORPHINE SULFATE IN SODIUM CHLORIDE, MORPHINE SULFATE IR, MORPHINE SULFATE-BUPIVACAINE HCL-SO, MORPHINE SULFATE-SODIUM CHLORIDE, MORPHINE SULFATE/SODIUM CHLORIDE, MORPHINE-DEXTROSE, MORPHINE-SODIUM CHLORIDE, MS CONTIN, MS/L, MS/L CONCENTRATE, MS/S, MSIR, NALOCET, NALOXONE HCL/PENTAZOCINE, NALOXONE HYDROCHLORIDE/PENTAZOCINE, NALOXONE/PENTAZOCINE, NARVOX, NINJACOF-XG, NORCET, NORCO, NOTUSS-AC, NOTUSS-PE, NOVAPLUS ALFENTANIL, NOVAPLUS FENTANYL, NOVAPLUS FENTANYL TRANSDERMAL SYSTE, NUCYNTA, NUCYNTA ER, NUMORPHAN HCL, OMS, ONCET, ONSOLIS, OPANA, OPANA ER, OPIUM, ORAL TRANSMUCOSAL FENTANYL CITRATE, ORAMORPH SR, ORLAAM, OXAYDO, OXECTA, OXY IR, OXYCODONE, OXYCODONE AND ACETAMINOPHEN, OXYCODONE CR, OXYCODONE HCL, OXYCODONE HCL AND ACETAMINOPHEN, OXYCODONE

HCL CR, OXYCODONE HCL-ACETAMINOPHEN, OXYCODONE HCL-ACETAMINOPHEN AVPAK, OXYCODONE HCL-ASPIRIN, OXYCODONE HCL-IBUPROFEN, OXYCODONE HCL-OXYCODONE TEREPHTHALA, OXYCODONE HCL/OXYCODONE TEREPHTHALA, OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE AND IBUPROF, OXYCODONE HYDROCHLORIDE CR, OXYCODONE HYDROCHLORIDE/ACETAMINOPH, OXYCODONE W/APAP, OXYCODONE W/ASPIRIN, OXYCODONE-ACETAMINOPHEN, OXYCODONE-APAP, OXYCODONE-ASPIRIN, OXYCODONE/ACETAMINOPHEN, OXYCODONE/APAP, OXYCONTIN, OXYCONTIN CR, OXYCONTIN HYDROCHLORIDE ER, OXYFAST, OXYMORPHONE HCL, OXYMORPHONE HYDROCHLORIDE, PALLADONE, PANACET 5/500, PANASAL 5/500, PANLOR, PANLOR DC, PANLOR SS, PANLOR-DC, PANLOR-SS, PENTAZOCIN/NALOXONE, PENTAZOCINE AND NALOXONE HYDROCHLOR, PENTAZOCINE HCL-ACETAMINOPHEN, PENTAZOCINE HCL-NALOXONE HCL, PENTAZOCINE HYDROCHLORIDE/NALOXONE, PENTAZOCINE/APAP, PENTAZOCINE/NALOXONE, PERCOCET, PERCODAN, PERCODAN DEMI, PERCOLONE, PERLOXX, PHENAPHEN W/CODEINE, PHENAPHEN-650 W/CODEINE, PHENDACOF PLUS, PHRENILIN W/CAFFEINE/CODEINE, PHRENILIN WITH CAFFEINE AND CODEINE, PLURATUSS, POLY HIST DHC, POLY-TUSSIN, POLY-TUSSIN AC, POLY-TUSSIN EX, POLYGESIC, PREMIERPRO RX ALFENTANIL HCL, PRIMALEV, PRIMLEV, PROCET, PROPAIN HC, PYREGESIC-C, RELATUSS HC, REMIFENTANIL HCL-SODIUM CHLORIDE, REMIFENTANIL HYDROCHLORIDE, REPREXAIN, RESCUDOSE, RID-A-PAIN W/CODEINE, RMS, RO-CODONE, ROXANOL, ROXANOL UD, ROXANOL-T, ROXICET, ROXICODONE, ROXICODONE INTENSOL, ROXIPRIN, ROXYBOND, RYBIX ODT, RYZOLT, SIMPLIST DILAUDID, SOMA COMPOUND W/CODEINE, STAGESIC, STAGESIC-10, SUBLIMAZE, SUBSYS, SUFENTA, SUFENTANIL CITRATE, SUFENTANIL CITRATE NOVAPLUS, SUFENTANIL CITRATE-BUPIVACAINE HCL-, SUFENTANIL CITRATE-ROPIVACAINE HCL-, SYMTAN, SYMTAN A, SYNALGOS-DC, T-GESIC, TALACEN, TALWIN, TALWIN COMPOUND, TALWIN LACTATE, TALWIN NX, THERACODOPHEN-325, THERACODOPHEN-750, THERACODOPHEN-LOW-90, THERATRAMADOL-60, THERATRAMADOL-90, TL-HIST CD, TL-HIST CM, TRAMADOL, TRAMADOL HCL, TRAMADOL HCL-ACETAMINOPHEN, TRAMADOL HCL/ACETAMINOPHEN, TRAMADOL HCL/ACETAMINOPHEN AVPAK, TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE & APAP, TRAMADOL HYDROCHLORIDE AND ACETAMIN, TRAMADOL HYDROCHLORIDE-ACETAMINOPHE, TRAMADOL HYDROCHLORIDE/ACETAMINOPHE, TRAMADOL HYDROCHLORIDE/APAP, TRAMADOL/ACETAMINOPHEN, TRAMADOL/APAP, TREZIX, TRI-VENT HC, TRICODE AR, TRICODE GF, TUSSPLEX, TUXARIN ER, TYLENOL W/CODEINE, TYLENOL W/CODEINE #1, TYLENOL W/CODEINE #2, TYLENOL W/CODEINE #3, TYLENOL W/CODEINE #4, TYLENOL W/CODEINE NO 4, TYLENOL WITH CODEINE, TYLENOL WITH CODEINE NO. 3, TYLENOL WITH CODEINE NO. 4, TYLOX, UGESIC, ULTIVA, ULTRACET, ULTRAM, ULTRAM ER, VANACET, VENDONE, VERDROCET, VICODIN, VICODIN ES, VICODIN HP, VICOPROFEN, VOPAC, XARTEMIS XR, XODOL, XODOL 5/300, XODOL 7.5/300. XOLOX, XTAMPZA ER, XYLON 10, Z-TUSS AC, Z-TUSS E, ZAMICET, ZERLOR, ZOHYDRO ER, ZOLVIT, ZUTRIPRO, ZYDONE

#### SSRI/SNRI

BRISDELLE, CELEXA, CITALOPRAM, CITALOPRAM HYDROBROMIDE, CYMBALTA, DERMACINRX DPN PAK, DESVENLAFAXINE, DULOXETINE, DULOXETINE HCL, DULOXETINE HCL AVPAK, DULOXETINE HYDROCHLORIDE, EFFEXOR, EFFEXOR XR, EFFEXOR-XR, ESCITALOPRAM, ESCITALOPRAM OXALATE, FETZIMA, FETZIMA TITRATION PACK, FLUOXETINE, FLUOXETINE HCL, FLUOXETINE HCL AVPAK, FLUOXETINE HYDROCHLORIDE, FLUVOXAMINE, FLUVOXAMINE MALEATE, GABOXETINE, IRENKA, KHEDEZLA, LEXAPRO, LUVOX, LUVOX CR, PAROXETIN, PAROXETINE, PAROXETINE HCL, PAROXETINE HCL AVPAK, PAROXETINE HYDROCHLORIDE, PAROXETINE MESYLATE, PAXIL, PAXIL CR, PEXEVA, PRISTIQ, PROZAC, PROZAC WEEKLY, RAPIFLUX, SARAFEM, SELFEMRA, SENTRAFLOX AM-10, SENTROXATINE, SERTRALINE, SERTRALINE HCL, SERTRALINE HYDROCHLORIDE, VENLAFAXINE, VENLAFAXINE HCL, VENLAFAXINE HCL AVPAK, VENLAFAXINE HCL XR, VENLAFAXINE HYDROCHLORIDE, VIIBRYD, VIIBRYD STARTER PACK, VIIBRYD TITRATION PACK, ZOLOFT

#### Supplementary Table 4. ICD-10 Diagnosis Codes for Falls and Fractures

Fall ICD-10-CM	Fracture IC	D-10-CM						
W00.x	S02.0XXA	S06.336A	S14.101A	S32.810B	S42.493A	S62.123B	S72.453B	S92.109A
W01.x	S02.0XXB	S06.337A	S14.102A	S32.811A	S42.493B	S62.126A	S72.453C	S92.109B
W05.x-W19.x	S02.101A	S06.338A	S14.103A	S32.811B	S42.496A	S62.126B	S72.456A	S92.201A
V00.11	S02.101B	S06.339A	S14.104A	S32.82XA	S42.496B	S62.133A	S72.456B	S92.201B
V00.13	S02.102A	S06.360A	S14.105A	S32.82XB	S42.90XA	S62.133B	S72.456C	S92.202A
V00.14	S02.102B	S06.361A	S14.106A	S32.89XA	S42.90XB	S62.136A	S72.499A	S92.202B
V00.15	S02.109A	S06.362A	S14.107A	S32.89XB	S42.91XA	S62.136B	S72.499B	S92.209A
V00.31	S02.109B	S06.363A	S14.111A	S32.9XXA	S42.91XB	S62.143A	S72.499C	S92.209B
V00.32	S02.2XXA	S06.364A	S14.112A	S32.9XXB	S42.92XA	S62.143B	S72.90XA	S92.213A
	S02.2XXB	S06.365A	S14.113A	S34.131A	S42.92XB	S62.146A	S72.90XB	S92.213B
	S02.30XA	S06.366A	S14.114A	S34.132A	S52.009A	S62.146B	S72.90XC	S92.216A
	S02.30XB	S06.367A	S14.115A	S34.139A	S52.009B	S62.153A	S72.90XE	S92.216B
	S02.31XA	S06.368A	S14.116A	S34.3XXA	S52.009C	S62.153B	S72.91XA	S92.223A
	S02.31XB	S06.369A	S14.117A	S42.009A	S52.011A	S62.156A	S72.91XE	S92.223B
	S02.32XA	S06.4X0A	S14.121A	S42.009B	S52.012A	S62.156B	S72.92XA	S92.226A
	S02.32XB	S06.4X1A	S14.122A	S42.013A	S52.019A	S62.163A	S72.92XE	S92.226B
	S02.400A	S06.4X2A	S14.123A	S42.013B	S52.023A	S62.163B	S82.009A	S92.233A
	S02.400B	S06.4X3A	S14.124A	S42.016A	S52.023B	S62.166A	S82.009B	S92.233B
	S02.401A	S06.4X4A	S14.125A	S42.016B	\$52.023C	S62.166B	S82.009C	S92.236A
	S02.401B	S06.4X5A	S14.126A	S42.019A	S52.026A	S62.173A	S82.101A	S92.236B
	S02.402A	S06.4X6A	S14.127A	S42.019B	S52.026B	S62.173B	S82.101B	S92.243A
	S02.402B	S06.4X7A	S14.131A	S42.023A	S52.026C	S62.176A	S82.102A	S92.243B
	S02.40AA	S06.4X8A	S14.132A	S42.023B	S52.043A	S62.176B	S82.102B	S92.246A
	S02.40AB	S06.4X9A	S14.133A	S42.026A	S52.043B	S62.183A	S82.109A	S92.246B
	S02.40BA	S06.5X0A	S14.134A	S42.026B	S52.043C	S62.183B	S82.109B	S92.253A
	S02.40BB	S06.5X1A	S14.135A	S42.033A	S52.046A	S62.186A	S82.109C	S92.253B
	S02.40CA	S06.5X2A	S14.136A	S42.033B	S52.046B	S62.186B	S82.161A	S92.256A
	S02.40CB	S06.5X3A	S14.137A	S42.036A	S52.046C	S62.233A	S82.162A	S92.256B
	S02.40DA	S06.5X4A	S14.151A	S42.036B	S52.099A	S62.233B	S82.169A	S92.301A
	S02.40DB	S06.5X5A	S14.152A	S42.109A	S52.099B	S62.236A	S82.201A	S92.301B
	S02.40EA	S06.5X6A	S14.153A	S42.109B	S52.099C	S62.236B	S82.201B	S92.302A
	S02.40EB	S06.5X7A	S14.154A	S42.113A	S52.109A	S62.309A	S82.201C	S92.302B
	S02.40FA	S06.5X8A	S14.155A	S42.113B	S52.109B	S62.309B	S82.202A	S92.309A
	S02.40FB	S06.5X9A	S14.156A	S42.116A	\$52.109C	S62.319A	S82.202B	S92.309B
	S02.42XA	S06.6X0A	S14.157A	S42.116B	S52.111A	S62.319B	S82.209A	S92.403A
	S02.42XB	S06.6X1A	S22.019A	S42.123A	S52.112A	S62.329A	S82.209B	S92.403B
	S02.600A	S06.6X2A	S22.019B	S42.123B	S52.119A	S62.329B	S82.209C	S92.406A
	S02.600B	S06.6X3A	S22.029A	S42.126A	S52.123A	S62.339A	S82.311A	S92.406B
	S02.601A	S06.6X4A	S22.029B	S42.126B	S52.123B	S62.339B	S82.312A	S92.503A
	S02.601B	S06.6X5A	S22.039A	S42.133A	S52.123C	S62.349A	S82.319A	S92.503B
	S02.602A	S06.6X6A	S22.039B	S42.133B	S52.126A	S62.349B	S82.401A	S92.506A
	S02.602B	S06.6X7A	S22.049A	S42.136A	S52.126B	S62.359A	S82.401B	S92.506B
	S02.609A	S06.6X8A	S22.049B	S42.136B	S52.126C	S62.359B	S82.401C	S92.819A
	S02.609B	S06.6X9A	S22.059A	S42.143A	S52.133A	S62.369A	S82.402A	S92.819B
	S02.610A	S06.890A	S22.059B	S42.143B	S52.133B	S62.369B	S82.402B	S92.909A
	S02.610B	S06.891A	S22.069A	S42.146A	S52.133C	S62.399A	S82.409A	S92.909B
	S02.611A	S06.892A	S22.069B	S42.146B	S52.136A	S62.399B	S82.409B	S99.109A
	S02.611B	S06.893A	S22.079A	S42.153A	S52.136B	S62.509A	S82.409C	S99.109B
	S02.612A	S06.894A	S22.079B	S42.153B	S52.136C	S62.509B	S82.53XA	S99.119A
	S02.612B	S06.895A	S22.089A	S42.156A	S52.189A	S62.513A	S82.53XB	S99.119B
	S02.620A	S06.896A	S22.089B	S42.156B	S52.189B	S62.513B	S82.53XC	S99.129A

S02.620B	S06.897A	S22.20XA	S42.199A	S52.189C	S62.516A	S82.56XA	S99.129B
S02.621A	S06.898A	S22.20XB	S42.199B	S52.209A	S62.516B	S82.56XB	S99.139A
S02.621B	S06.899A	S22.39XA	S42.209A	S52.209B	S62.523A	S82.56XC	S99.139B
S02.622A	S06.9X0A	S22.39XB	S42.209B	S52.209C	S62.523B	S82.63XA	S99.149A
S02.622B	S06.9X1A	S22.49XA	S42.213A	S52.279A	S62.526A	S82.63XB	S99.149B
S02.630A	S06.9X2A	S22.49XB	S42.213B	S52.279B	S62.526B	S82.63XC	S99.199A
S02.630B	S06.9X3A	S22.5XXA	S42.216A	S52.279C	S62.609A	S82.66XA	S99.199B
S02.631A	S06.9X4A	S22.5XXB	S42.216B	S52.309A	S62.609B	S82.66XB	
S02.631B	S06.9X5A	S22.9XXA	S42.253A	S52.309B	S62.619B	S82.66XC	
S02.632A	S06.9X6A	S22.9XXB	S42.253B	S52.309C	S62.629A	S82.811A	
S02.632B	S06.9X7A	S24.101A	S42.256A	S52.509A	S62.629B	S82.812A	
S02.640A	S06.9X8A	S24.102A	S42.256B	S52.509B	S62.639A	S82.819A	
S02.640B	S06.9X9A	S24.103A	S42.293A	S52.509C	S62.639B	S82.821A	
S02.641A	S12.000A	S24.104A	S42.293B	S52.521A	S62.649A	S82.822A	
S02.641B	S12.000B	S24.111A	S42.295A	S52.522A	S62.649B	S82.829A	
S02.642A	S12.001A	S24.112A	S42.296A	S52.529A	S62.659A	S82.831A	
S02.642B	S12.001B	S24.113A	S42.296B	S52.539A	S62.659B	S82.831B	
S02.650A	S12.100A	S24.114A	S42.309A	S52.539B	S62.669A	S82.832A	
S02.650B	S12.100B	S24.131A	S42.309B	S52.539C	S62.669B	S82.832B	
S02.651A	S12.101A	S24.132A	S42.399A	S52.549A	S62.90XA	S82.839A	
S02.651B	S12.101B	S24.133A	S42.399B	S52.609A	S62.90XB	S82.839B	
S02.652A	S12.200A	S24.134A	S42.409A	S52.609B	S72.009A	S82.839C	
S02.652B	S12.200B	S24.151A	S42.409B	S52.609C	S72.009B	S82.843A	
S02.66XA	S12.2018	S24.152A	S42.413A	S52.621A	S72.009C	S82.843B	
S02.66XB	S12.201A	S24.153A	S42.413B	S52.622A	S72.309A	S82.843C	
S02.670A	S12.300A	S24.154A	S42.416A	S52.629A	S72.309B	S82.846A	
S02.670B	S12.300B	S32.10XA	S42.416B	S52.90XA	S72.309C	S82.846B	
S02.671A	S12.301A	S32.10XB	S42.433A	S52.90XB	S72.409A	S82.846C	
S02.671B	S12.301B	S32.2XXA	S42.436A	S52.90XC	S72.409B	S82.853A	
S02.672A	S12.400A	S32.2XXB	S42.443A	S52.91XA	S72.409C	S82.853B	
S02.672B	S12.400B	S32.309A	S42.446A	S52.91XB	S72.413A	S82.853C	
S02.69XA	S12.401A	S32.309B	S42.453A	S52.92XA	S72.413B	S82.856A	
S02.69XB	S12.401B	S32.409A	S42.453B	S52.92XB	S72.413C	S82.856B	
S02.91X6	S12.500A	S32.409B	S42.456A	S59.109A	S72.416A	S82.856C	
S02.91XA	S12.500B	S32.501A	S42.456B	S62.009A	S72.416B	S82.899A	
S02.92X6	S12.501A	S32.501B	S42.463A	S62.009B	S72.416C	S82.899B	
S02.92XA	S12.501B	S32.502A	S42.463B	S62.109A	S72.443A	S82.899C	
S06.330A	S12.600A	S32.502B	S42.466A	S62.109B	S72.443B	S82.90XA	
S06.331A	S12.600B	S32.509A	S42.466B	S62.113A	S72.443C	S82.90XB	
S06.332A	S12.601A	S32.509B	S42.473A	S62.113B	S72.446A	S82.91XA	
S06.333A	S12.601B	S32.609A	S42.473B	S62.116A	S72.446B	S82.91XB	
S06.334A	S12.8XXA	S32.609B	S42.476A	S62.116B	S72.446C	S82.92XA	
S06.335A	S12.9XXA	S32.810A	S42.476B	S62.123A	S72.453A	S82.92XB	

stratifying by Alzneimer s/Non-Alzneimer s										
		Alzheimer's	No Alzheimer's							
Drug Combo	Benzo + Opioid	REF	REF							
	≥3 combination	1.26 (0.99, 1.59)	1.71 (1.22, 2.39)							
	Benzo + GABA	0.87 (0.72, 1.05)	1.53 (1.16, 2.02)							
	Benzo + SSRI or SNRI	0.70 (0.54, 0.91)	1.30 (0.92, 1.85)							
	GABA + SSRI or SNRI	1.00 (0.82, 1.22)	1.17 (0.86, 1.59)							
	Opioid + GABA	1.10 (0.92, 1.32)	1.41 (1.07, 1.87)							
	Opioid + SSRI or SNRI	1.04 (0.86, 1.26)	1.27 (0.93, 1.74)							

## Supplementary Table 5. Stratified Hazard Ratios<sup>a</sup> for the Association of Drug Combination and Fall, Stratifying by Alzheimer's/Non-Alzheimer's

<sup>a</sup>Based off the fully adjusted multivariate model (model 3) from the main analysis.

#### Supplementary Table 6. Standardized Differences<sup>a</sup> for all Pairwise Comparisons Before and After Inverse Probability of Treatment Weighting with Propensity Score

	Standardized Differences Compared to Benzo/Opioid Before IPTW with Propensity Score					Standardized Differences Compared to Benzo/Opioid After IPTW with Propensity Score - Falls Model					Standardized Differences Compared to Benzo/Opioid After IPTW with Propensity Score - Fractures Model										
	Benzo/ Benzo/ Onioid/ Onioid/ GABA/ 3+ Max					Benzo/ Benzo/ Onioid/ Onioid/ GABA/ 3+ MAX				Benzo/ Benzo/ Opioid/ Opioid/ GABA/ 3+ MAX					MAX						
	GABA	SSRI	GABA	SSRI	SSRI	Combo	Diffa	GARA	SSRI	GABA	SSRI	SSRI	Combo	Diffa	GARA	SSRI	GABA	SSRI	SSRI	Combo	Diffa
Sev	0.1464	0.0668	0.0207	-0.0207	0.071	0.0851	0.1464	-0.0054	-0.0075	-0.0036	-0.0083	0.0017	-0.0131	0.0121	-0.0051	-0.0067	-0.0021	-0.0083	0.0020	-0.0143	0.01/13
Δσρ	0.1404	0.0008	0.0307	0.0237	0.0561	0.0001	0.1404	0.0034	0.0075	0.0030	0.0003	0.0017	0.0218	0.0131	0.0000	0.0007	-0.0031	0.0003	0.0023	0.0218	0.0143
Bace	0.0302	0.1511	0.0207	0.0332	0.0501	0.0614	0.1257	0.0233	0 0789	0	0.0210	0.0210	0.0642	0.0233	0.0255	0 0789	0	0.0210	0.0210	0.044	0.0235
Region	0.2450	0 1665	0.0043	0.0337	0 1315	0.0587	0.2450	0.044	0.0789	0 0289	0.0289	0	0.0042	0.0289	0.044	0.0789	0.0289	0 0289	0	0.0289	0.0289
Original Entitlement	0 2563	0 1666	0.0551	-0.0339	0 1263	-0.0683	0 2563	-0.0104	-0.0115	-0.0032	-0.0051	0 0095	-0.0018	0.0115	-0.0103	-0.0119	-0.0031	-0.0051	0 0095	-0.0037	0.0119
Medicaid Dual Eligibility	-0 1911	-0 1131	0.0144	0.0911	-0.0116	0.079	0 1911	0.0108	0.0064	-0.0037	-0.0002	-0.0087	-0.0075	0.0108	0.0109	0.008	-0.0037	-0.0004	-0.0087	-0.0051	0.0109
History of Fall	-0.0343	-0.0504	0.1333	0.0406	0.1054	0.1461	0.1461	0.0078	-0.0017	0.0013	-0.016	-0.0073	-0.0112	0.016	0.0105	0.000	0.0007	0.0001	0.0007	0.0001	0.0105
History of Fracture	-0.0381	-0.0599	0.0804	0.0273	0.0392	0.1019	0.1019	0	0	0	0	0	0	0	0.0125	0.0136	0.0023	-0.0032	0.0007	0.0064	0.0136
History of Hospitalization	-0.1479	-0.1045	0.0974	0.1497	0.0626	0.1776	0.1776	0.0241	0.0131	0.0038	0.0104	-0.0089	-0.0038	0.0241	0.024	0.0144	0.0034	0.0107	-0.0085	-0.0019	0.024
Alcohol Use Disorders	-0.0122	0.0016	0.039	0.0436	0.0467	0.0321	0.0467	0.0146	0.0032	-0.0004	0.0092	0.0079	-0.0027	0.0146	0.0139	0.0037	-0.001	0.0091	0.0075	-0.0019	0.0139
Alzheimer/Dementia	0.0994	0.4384	0.1967	0.0875	0.1852	0.1694	0.4384	0.017	0.0079	-0.0084	-0.0035	-0.002	-0.0092	0.017	0.0175	0.0092	-0.0078	-0.0023	-0.002	-0.0098	0.0175
Arthritis	-0.2094	-0.083	0.1064	0.1546	-0.0055	0.0192	0.2094	-0.003	-0.0082	-0.0147	-0.0048	-0.0048	-0.0054	0.0147	-0.0029	-0.0082	-0.015	-0.0043	-0.0048	-0.0038	0.015
Asthma	-0.0443	-0.0334	-0.0059	0.0327	0.0317	0.0278	0.0443	0.0002	-0.0039	-0.0203	-0.014	-0.0014	-0.0209	0.0209	0.0003	-0.0029	-0.02	-0.014	-0.0003	-0.0211	0.0211
Cancer	-0.0218	0.0309	-0.0132	-0.0106	-0.0149	-0.0285	0.0309	-0.0017	-0.0008	-0.0049	0.004	-0.0016	0.0086	0.0086	-0.0026	-0.0013	-0.0051	0.0042	-0.0027	0.0106	0.0106
CKD	-0.1258	-0.0386	0.0873	0.1805	0.1347	0.0999	0.1805	0.0114	0.0153	0.0053	0.0137	-0.0011	-0.002	0.0153	0.0113	0.0142	0.0056	0.0131	-0.0024	-0.0008	0.0142
COPD	-0.1766	-0.1467	-0.0095	0.0445	-0.0413	0.0384	0.1766	0.0138	0.0069	0.0046	0.0047	-0.0036	-0.0085	0.0138	0.0139	0.0089	0.0045	0.0048	-0.0033	-0.0075	0.0139
Depression	0.4736	0.1887	0.5993	0.181	0.6425	0.5622	0.6425	0.0229	0.0041	-0.0059	0.0105	0.0041	-0.0009	0.0229	0.0231	0.0061	-0.0064	0.0111	0.0051	-0.0009	0.0231
Diabetes	-0.0601	0.0525	0.093	0.219	0.2556	0.1142	0.2556	-0.0002	0.0069	-0.0022	-0.0028	-0.0032	-0.0147	0.0147	-0.0007	0.0061	-0.0035	-0.0036	-0.0039	-0.0135	0.0135
Drug Abuse	-0.2264	-0.165	-0.0042	0.0647	-0.1161	0.0578	0.2264	0.0167	0.019	0.0031	0.0016	0.0012	-0.0067	0.019	0.0178	0.0189	0.0026	0.0015	0.0014	-0.0055	0.0189
Epilepsy	0.0042	0.032	0.0456	0.0379	0.0691	0.1023	0.1023	0.0184	0.0008	0.0006	-0.0042	-0.0031	-0.0047	0.0184	0.0189	0	0.0009	-0.0037	-0.0027	-0.005	0.0189
Hearing Impairment	0.0747	0.05	0.0693	0.0545	0.0949	0.026	0.0949	-0.0112	-0.0077	-0.0069	-0.0001	0.0021	0.0029	0.0112	-0.0112	-0.0076	-0.0064	0	0.0012	0.0033	0.0112
Hip/Pelvic Fracture	-0.0064	-0.0535	0.0673	0.0014	0.0078	0.0615	0.0673	0.0139	-0.0027	-0.0034	-0.0035	-0.0011	0.0049	0.0139	0.0148	0.0009	-0.0028	-0.0032	-0.0018	0.0068	0.0148
Liver Disease	-0.0367	-0.0056	0.0033	0.0465	0.0243	0.0387	0.0465	-0.0127	0.0033	-0.0257	0.0101	-0.0315	0.0005	0.0315	-0.0135	0.0031	-0.0258	0.0096	-0.0309	0.0003	0.0309
Migraine/Headache	0.0004	0.0534	-0.0144	-0.0193	0.0261	0.0542	0.0542	-0.0025	-0.0113	-0.005	0.0061	-0.0072	-0.0078	0.0113	-0.0025	-0.0098	-0.0035	0.0059	-0.008	-0.0082	0.0098
Mobility Impairment	0.0101	0.0326	0.0845	0.1308	0.1654	0.1066	0.1654	0.0081	0.0018	-0.0059	-0.0084	-0.0108	-0.0063	0.0108	0.0065	0.0035	-0.0057	-0.0083	-0.011	-0.0065	0.011
Obesity	-0.0384	0.0331	0.1365	0.1948	0.2336	0.1589	0.2336	0.0119	0.0144	0.008	0.0072	0.0069	0.0029	0.0144	0.0122	0.015	0.0076	0.0066	0.0068	0.0026	0.015
Osteoporosis	-0.0125	-0.005	0.052	0.0088	-0.007	-0.0021	0.052	-0.0137	-0.012	-0.009	-0.005	-0.0056	-0.006	0.0137	-0.0135	-0.012	-0.0083	-0.004	-0.0058	-0.0041	0.0135
Spine Injury	-0.0516	-0.0382	0.025	0.0232	0.0135	0.0484	0.0516	0.0127	0.0024	-0.002	-0.0015	0.002	-0.0034	0.0127	0.0124	0.0035	-0.0013	-0.0013	0.0027	-0.0025	0.0124
Vision Impairment	0.1008	0.0973	-0.0147	-0.0037	0.0801	0.0324	0.1008	-0.0112	-0.0084	-0.0073	0.001	-0.0036	-0.0041	0.0112	-0.0108	-0.008	-0.0067	0.0011	-0.0035	-0.0034	0.0108

<sup>a</sup>Standardized differences across six pairwise comparisons between each drug combination group and the opioid/benzodiazepine group before IPTW with propensity scor and after IPTW with propensity score for the falls and fractures models.

<sup>a</sup>The maximum difference is the absolute value of the maximum standardized difference across six pairwise comparisons between each drug combination group and the opioid/benzodiazepine group, presented to illustrate the covariate balance after IPTW with propensity score.

	Excluding Cancer P	Patients <sup>a</sup> (n=41047)	3 Month Lookback <sup>a</sup> (n=25040)				
Drug Combination	Fall	Fracture	Fall	Fracture			
Benzo + Opioid	REF	REF	REF	REF			
≥3 drugs	1.41 (1.15, 1.73)	1.43 (1.04, 1.96)	1.21 (0.90, 1.62)	1.32 (0.86, 2.02)			
Benzo + GABA	1.04 (0.88, 1.23)	0.75 (0.56, 0.99)	1.01 (0.82, 1.25)	0.76 (0.53, 1.08)			
Benzo + SSRI/SNRI	0.90 (0.72, 1.12)	0.82 (0.57, 1.18)	0.77 (0.57, 1.03)	0.64 (0.39, 1.06)			
GABA + SSRI/SNRI	1.00 (0.83, 1.20)	1.05 (0.79, 1.40)	1.02 (0.80, 1.30)	1.06 (0.73, 1.53)			
Opioid + GABA	1.16 (0.99, 1.37)	1.21 (0.94, 1.56)	1.32 (1.08, 1.62)	1.44 (1.06, 1.95)			
Opioid + SSRI/SNRI	1.07 (0.89, 1.28)	1.15 (0.87, 1.51)	1.17 (0.94, 1.46)	1.12 (0.80, 1.59)			

## Supplementary Table 7. Sensitivity Analyses

<sup>a</sup>The sensitivity analyses were fully adjusted for all demographic and clinical characteristics, as in the fully adjusted multivariable model from the main analysis, but hazard ratios characteristics are not presented in this table for the sake of brevity.

#### Supplementary Table 8. Demographics Comparison the Cohorts from the Primary Analysis and the Sensitivity Analyses

	• • • •	Primary	Primary Analysis		ncer	3 Month Lookback		
		N	%	N	%	N	%	
	Total	47.964	100%	41.047	100%	25.040	100%	
Drug Combo	Benzo/Opioid	10.261	21.4%	8.750	21.3%	5.150	20.6%	
0	3+ Combo	5.499	11.5%	4.718	11.5%	2.644	10.6%	
	Benzo + GABA	2.775	5.8%	2.394	5.8%	1.261	5.0%	
	Benzo + SSRI or SNRI	9 541	19.9%	8 209	20.0%	5 215	20.8%	
	GABA + SSRI or SNRI	4 4 2 0	9.2%	3 720	9.1%	2 313	9.2%	
	Onioid + GABA	8 625	18.0%	7 395	18.0%	4 705	18.8%	
	Opioid + SSPL or SNPL	6 843	1/ 2%	5 861	1/ 2%	3 752	15.0%	
Sov		10 570	22.0%	8 7/6	21 3%	5,752	22.6%	
Jex	Female	37 39/	78.0%	32 301	78 7%	10 380	77.4%	
Age (mean SD)	remale	75 9	7 1	75.8	70.7%	76.4	73	
Age Category	65-74	22 662	47.2%	19 775	48.2%	11 217	44.8%	
he category	75-84	17 993	37.5%	15 134	36.9%	9 619	38.4%	
	85+	7.309	15.2%	6.138	15.0%	4,204	16.8%	
Race	White	42.008	87.6%	35.846	87.3%	21.690	86.6%	
	Black	2.579	5.4%	2.226	5.4%	1.416	5.7%	
	Hispanic	2,168	4.5%	1,929	4.7%	1,239	4.9%	
	Other	1.209	2.5%	1.046	2.5%	, 695	2.8%	
Region	MW	11,107	23.2%	9,571	23.3%	5,706	22.8%	
5	NE	8,204	17.1%	6,853	16.7%	4,524	18.1%	
	SO	20,784	43.3%	17,907	43.6%	10,588	42.3%	
	WE	7,869	16.4%	6,716	16.4%	4,222	16.9%	
Original	Disabled/ESRD	13,297	27.7%	11,603	28.3%	6,352	25.4%	
Entitlement	Old Age	34,667	72.3%	29,444	71.7%	18,688	74.6%	
Medicaid Dual	No	35,329	73.7%	29,985	73.1%	18,491	73.8%	
Eligibility	Yes	12,635	26.3%	11,062	26.9%	6,549	26.2%	
Number of days	Mean, SD	32.0	32.3	32.4	32.5	28.2	26.4	
on drug combo	Median, Q1-Q3	26	14-30	26	14-30	23	13-30	
History of Fall		8,437	17.6%	7,090	17.3%	4,261	17.0%	
History of Fracture	2	3,537	7.4%	2,921	7.1%	1,829	7.3%	
History of Hospita	lization	20,997	43.8%	17,213	41.9%	10,770	43.0%	
Chronic	Alcohol Use Disorders	2,131	4.4%	1,830	4.5%	1,100	4.4%	
Conditions	Alzheimer/Dementia	10,202	21.3%	8,748	21.3%	5,474	21.9%	
	Arthritis	37,490	78.2%	32,155	78.3%	19,343	77.2%	
	Asthma	6,543	13.6%	5,560	13.5%	3,391	13.5%	
	Cancer	6,917	14.4%	0	0.0%	3,702	14.8%	
	CKD	18,364	38.3%	15,378	37.5%	9,426	37.6%	
	COPD	14,217	29.6%	11,790	28.7%	7,098	28.3%	
	Depression	29,905	62.3%	25,512	62.2%	14,/33	58.8%	
	Diabetes	17,962	37.4%	15,305	37.3%	9,254	37.0%	
	Drug Ose Disorder	5,038	10.5%	4,302	10.5%	2,103	8.0%	
	Ephepsy Hearing Impairment	2,075	4.5% 0.5%	1,707	4.4% 0.2%	2,001	4.2%	
		4,555	9.5% 2.1%	3,823	3.3% 2.0%	522	5.5% 2.1%	
	Liver Disease	3 870	2.1 <i>/</i> 0 8.1%	3 149	2.0%	2 000	8.0%	
	Migraine/Headache	4.362	9.1%	3,799	9.3%	2,000	8.7%	
	Mobility Impairment	2,744	5.7%	2.357	5.7%	1.445	5.8%	
	Obesity	13,994	29.2%	11.994	29.2%	6,995	27.9%	
	Osteoporosis	7,817	16.3%	6.466	15.8%	4,020	16.1%	
	Spine Injury	1.154	2.4%	939	2.3%	573	2.3%	
	Vision Impairment	14,508	30.2%	12,410	30.2%	7,713	30.8%	